SUMMARY
Autoimmunity leading to rheumatoid arthritis involves CD4+T-cell recruitment into synovial tissue. However, metabolic conditions supporting the survival and pro-inflammatory effector functions of these tissue-invading T cells remain poorly understood. Lipidomic analysis identified the inflamed synovium as a lipid-rich environment. In functional studies, administration of the free fatty acid oleic acid exacerbated synovitis. Tissue-invading CD4+T-cells responded to fatty acid with rapid cell lysis, releasing cytoplasmic and nuclear content into the extracellular space. This T-cell lytic death required sequestration of the pore-forming molecule Gasdermin D and the acyltransferase zDHHC5 to lipid droplets, which translocated to the plasma membrane to trigger membrane rupture and pyroptotic cell death. Targeting lipid droplet formation in CD4+T-cells through perilipin-2 knockdown or inhibiting gasdermin activation by blocking protein acylation proved highly effective in suppressing synovitis. Thus, autoimmune CD4+T-cells lack metabolic resilience, are primed to undergo pyroptosis in lipid-rich environments and deliver pro-inflammatory cargo to surrounding tissue.
Keywords: T cell, lipid droplet, Gasdermin D, pyroptosis, protein S-acylation, inflammation, autoimmune disease
Graphical Abstract

INTRODUCTION
Throughout a person’s lifetime, approximately 10% of the population is diagnosed with a clinically significant autoimmune disease1, with no curative interventions currently available to restore immune tolerance. Chronicity of tissue inflammation presents a major challenge, and recent data have begun to illuminate antigen-independent factors, such as the metabolic restructuring of key effector cells that sustain inflammatory responses2. In CD4+T-cells from patients with rheumatoid arthritis (RA), defective nuclear and mitochondrial DNA repair leads to metabolic deficiencies3, lysosomal underperformance4,5, and endoplasmic reticulum stress, transforming them into pro-inflammatory and tissue-damaging effector cells.6 The impact of these bioenergetic deficiencies on T-cell longevity and function within the tissue environment remains unclear.
Inflammation-promoting CD4+T-cells must invade tissue spaces, survive, and interact with immune and stromal cells. The tissue-resident CD4+T-cells found in the rheumatoid joint are predominantly central memory and effector memory cells4,7, while naïve CD4+T-cells are retained in lymph nodes, where they initially encounter antigens. Central memory and effector memory T-cells are high-turnover populations, exhibiting average intermitotic (doubling) times of 15–48 days respectively8, imposing significant proliferative stress and high bioenergetic and biosynthetic demands.
The synovial tissue is a glucose-starved enviroment9, favoring survival of glucose-independent cells. As such, it provides a haven for CD4+T-cells with downregulated extramitochondrial glycolysis10 and limited capacity for mitochondrial ATP production.11,12 Synovial tissue macrophages sustain their functions by accessing amino acids like glutamine and glutamate.5,13 In RA CD4+T-cells, glutamine anaplerosis is compromised due SUCLG1 downregulation and reversal of the tricarboxylic acid cycle.14 Consequently, mitochondrially impaired RA CD4+T-cells accumulate intracellular acetyl-CoA15, raising the critical question of how they manage extra- and intracellular lipids. In the case of tumor-infiltrating CD8+T-cells, upregulation of acetyl-CoA carboxylase and insufficient lipid catabolism threatens their survival and functional competence.16
To mitigate lipid toxicity, cells store neutral lipids such as triglycerides and cholesterol esters in lipid droplets (LDs). Once thought to be mere fat storage sites, LDs are now recognized as dynamic cytoplasmic organelles that play crucial roles in lipid metabolism and cellular energy homeostasis.17–20 LD proteomes are highly dynamic, with proteins involved in metabolism, signaling, and stress responses being recruited to or excluded from LD surfaces.21,22 Highly mobile and capable of interacting with nearly every organelle, LDs act as portable signaling hubs, pivotal for maintaining cellular bioenergetics and providing buffering capacity during cellular stress responses.17 In myeloid cells, LDs respond to danger-associated signals and serve as platforms for assembling inflammasome components.23–26
In this study, we have identified T-cell lipid processing as a critical mechanism in sustaining chronic inflammation. Our findings demonstrate that the tissue exerts metabolic control over infiltrating T cells, transforming them into pro-inflammatory effector cells. Quantification of free fatty acids (FFAs) revealed that inflamed synovial tissue constitutes a lipid-rich environment, and treatment of humanized mice with oleic acid (OAc) identified FFA as inflammatory accelerators. RA CD4+T-cells, unable to metabolize lipids, arrived at this FFA-rich tissue site already filled with LDs. Mitochondrial impairment of RA CD4+T-cells caused the translocation of two PM proteins to the LD surface: the pore-forming molecule GSDMD and the S-acyl transferase zDHHC5. Lipid stress initiated the rapid relocation of GSDMD+-zDHHC5+-LDs to the PM, triggering highly inflammatory pyroptotic cell death. Disrupting LD formation through perilipin-2 knockdown or inhibiting protein S-acylation effectively protects the tissue from inflammatory damage. Together, these findings elucidate a molecular mechanism by which the tissue microenvironment and LDs amplify inflammation: metabolically exhausted CD4+T-cells are unable to withstand the lipid-rich environment and undergo pyroptosis. LDs loaded with GSDMD and its lipidating enzyme zDHHC5 transform such metabolically stressed CD4+T-cells into drivers of chronic inflammation.
RESULTS
Free fatty acids (FFA) deposited in the rheumatoid joint exacerbate synovial inflammation.
The synovial joint is a glucose-depleted and glutamine-rich environment9, requiring metabolic adaptations of invading immune cells. CD4+T-cells account for ~30% of synovium-resident cells27,28 and have a signature metabolic exhaustion4,13, including low mitochondrial output, low glycolytic activity, shunting towards the pentose phosphate pathway, and limited utilization of amino acids, such as glutamine.4 To define bioenergetic resources for tissue-infiltrating CD4+T-cells, we quantified FFAs in freshly collected synovial biopsies (Figure 1A). Tissue FFA concentrations were about 100-fold higher than steady-state plasma levels in humans. Notably, tissue inflammation scores were closely correlated with increasing FFA concentrations. Oil Red O staining revealed diffuse deposition of neutral lipids, occupying the extracellular space between cells. Neutral lipid staining intensities correlated closely with tissue inflammation (Figure 1B).
Figure 1. FFA are deposited in the rheumatoid joint and exacerbate synovial tissue inflammation.

(A) Correlation of FFA concentrations and inflammation scores in rheumatoid synovium (n=20).
(B) RA synovial tissue sections were stained with Oil Red O. Intensities were quantified in tissues with low and high IS (Inflammation scores) (n=6 each).
(C-J) NSG mice engrafted with human synovium were immuno-reconstituted with human peripheral blood mononuclear cells. Chimeric mice were treated with vehicle or oleic acid (OAc;10 mg/kg) for one week. Explanted synovial tissues were processed for histology, immunofluorescence, and flow cytometry.
(C) Representative synovial tissue sections (H&E).
(D) Histomorphometric analysis of tissue sections to quantify frequencies of lymphocytes, macrophages, stromal cells and dead cells.
(E) Synovial tissue sections were stained with BOPIDY493/503 and nuclei marked with DAPI.
(F-I) Tissue infiltrating cells in vehicle vs OAc-treated grafts quantified by flow cytometry.
(F) Frequencies of BODIPY493/503+CD4+T-cells.
(G) Frequencies of CD68+ macrophages and TNF-producing CD68+macrophages.
(H) Frequencies of tissue-infiltrating CD4+T-cells.
(I) Frequencies of TNF-α and IFN-γ-producing CD4+T-cells.
(J) Correlation between frequencies of BODIPY493/503+ and IFN-producing CD4+T-cells.
All data are mean ± SEM with individual values shown. Unpaired Mann-Whitney-Wilcoxon rank test (B,D, F,G,H,I). Spearman correlation coefficient (J). Scale bar, 50μm.
Synovial FFA enrichment raised the question of whether lipids possess pro-inflammatory functions. We investigated the impact of FFA on disease activity in a human synovium-NSG mouse model. NSG mice were engrafted with human synovial tissues and reconstituted with patient-derived peripheral blood mononuclear cells (PBMC). Chimeras were treated with intraperitoneal injections of oleic acid (OAc; 10 mg/kg) for one week (Figure S1A). We chose OAc as a representative monounsaturated omega-9 fatty acid (18:1 cis-9) that is enriched in RA synovial tissue.29,30 OAc treatment markedly exacerbated synovial tissue inflammation (Figure 1C). OAc-treated grafts were densely infiltrated by lymphocytes and macrophages, accrued dead cells, and lipid deposits (Figure 1C-E). OAc treatment caused LD accumulation within tissue-infiltrating CD4+T-cells (Figure 1F), and enhanced cytokine production by tissue macrophages and CD4+T-cells (Figure 1G-I). Frequencies of IFN-γ+CD4+T-cells correlated with LD formation and cell death rates (Figure 1J, Figure S1B), linking lipid-induced inflammation to cellular death. Together, these data identified FFA as inflammatory stimuli, activating both tissue T-cells and macrophages and inducing cell death.
RA CD4+T cells are loaded with intracellular lipid droplets rich in oleic acid (OAc).
Having identified FFA deposits as a feature of the inflamed joint, we aimed to investigate how such FFA affect the survival and function of tissue-infiltrating CD4+T cells. We analyzed intracellular FFA and LD accumulation as a proxy for intracellular FFA storage. Patients with psoriatic arthritis (PsA) served as inflammatory disease controls. Compared to controls, RA CD4+T-cells had ~40% more intracellular FFAs (Figure 2A). We isolated LD from CD4+T-cells and performed lipidomic analysis to compare the FFA distribution in RA and healthy LD. Two FFAs, OAc and myristic acid were significantly enriched in RA LD, suggesting that RA CD4+T-cells have access to OAc-enriched lipid stores (Figure 2B). Notably, patient-derived CD4+T-cells accumulated reduced but not oxidized FFA (Figure 2C). Transmission electron microscopy visualized dense LD clusters almost exclusively in RA CD4+T-cells cells (Figure 2D). In a cross-sectional cohort of 17 patients with RA, the reduced/oxidized FFA ratio was closely correlated with the clinical disease activity index (CDAI) (Figure 2E). Consistently, highly active RA was associated with the accrual of un-oxidized fatty acids in CD4+T-cells (Figure S2A-B).
Figure 2. Metabolically exhausted CD4+T-cells accrue intracellular lipids.

Peripheral blood CD4+CD45RO−T-cells isolated from healthy controls, patients with RA or PsA were stimulated for 72h.
(A) FFAs were quantified in CD4+T-cell lysates (n=6/group).
(B) Lipid droplets were isolated from control and RA CD4+T-cells and FFAs were quantified by LC-MS/MS. Data are shown as a Z-score heatmap, with values normalized to the internal standard (n=4/group).
(C) CD4+T-cells were stained with BODIPY581/591-C11 and reduced and oxidized FFAs were measured by flow cytometry. Mean fluorescence intensities (MFI) from n=6/group are shown.
(D) Representative electron microscopy images from healthy and RA CD4+T-cells. Purple arrows indicate lipid droplets. 30 cells were examined from each of 3 controls and 3 RA patients. Scale bar; 0.5μm.
(E) Ratios of reduced/oxidized FFAs in CD4+T-cells were correlated with the clinical disease activity index (CDAI) in 17 patients.
(F) Intracellular ATP was quantified in control and RA CD4+T-cells (n=6 each).
(G) CD4+T-cells from healthy controls(n=8) and RA (n=8) were stained with BODIPY493/503, TMRM, and ER-Tracker. Correlations of ER size (ER-Tracker) vs. intracellular lipids (BODIPY493/503) and ER-Tracker vs. TMRM are shown. Grey dots; healthy controls. Pink dots; RA.
(H) Representative immunofluorescence images showing lipid droplet accumulation in the uropod of RA CD4+T-cells. Plasma membranes (PM;WGA;red), lipid droplets (BODIPY493/503;green), and nuclei (DAPI;blue). White dashed lines mark cell perimeters. (n=6/group). Scale bar; 5μm.
(I) Representative electron microscopy images from control and RA CD4+T-cells (n=3 each). Purple arrows mark LDs, blue dashed lines show PM, and orange arrows indicate the LD-to-PM distance. Scale bar; 0.5 μm.
(J) Enumeration of LDs in direct contact with the PM (left) and LD-to-PM distances (right); 50 cells/sample.
(K-L) Lipid-induced integration of PLIN2 into the plasma membrane. CD4+T-cells were treated with increasing doses of OAc, plasma membranes were isolated and immunoblotted for PLIN2, CD3, CD44, GAPDH, and β-actin. Bar graphs show PLIN2 quantification normalized to CD3 and β-actin, respectively. Data from 3 experiments.
All data are mean ± SEM with individual data points shown. One-way ANOVA with Dunnett’s multiple comparisons test (A-C,L). Spearman correlation coefficient (E,G). Unpaired Mann-Whitney-Wilcoxon rank test (F,J).
Given the unexpected finding that production and storage of reduced intracellular lipids distinguished RA and healthy CD4+T-cells, we focused on the metabolic competence of RA T-cells13. Gene expression profiling demonstrated a bias towards lipogenesis in RA CD4+T-cells and upregulation of CD36, while other fatty acid transporters were unchanged (Figure S2C). RA CD4+T-cells responded to stimulation with low ATP production, confirming our prior data of mitochondrial deficiency15. Additionally, RA CD4+T-cells accumulated acetyl-CoA and citrate (Figure 2F, Figure S2D-E), compatible with a defect in lipid catabolism. LD are born in the ER, prompting us to assess ER size and ER stress markers. Higher BODIPY493/503 signal was associated with larger ER-size in individual CD4+T-cells (Figure 2G). Correlation analysis revealed a significant inverse relationship between ER size (ER-Tracker) and mitochondrial fitness (mitochondrial membrane potential; TMRM or mitoROS) (Figure 2G, Figure S2F). ER size expansion in RA CD4+T-cells was associated with the upregulation of canonical ER stress markers (Figure S2G). Co-localization studies placed LD closely to mitochondria in healthy CD4+T-cells and geographically separated in RA CD4+T-cells (Figure S3A). Uropodal accumulation of LD, distant from perinuclear mitochondria, strongly suggested that RA CD4+T-cells failed to catabolize FFAs and instead allocated them to storage. Accordingly, inhibiting mitochondrial ATP synthase with oligomycin was sufficient to expand ER membranes (Figure S3B), and thus LD biogenesis, linking inappropriate T-cell lipid cargo to mitochondrial failure.
Placing LD formation into the context of interorganelle communication prompted us to define the subcellular distribution of LD and map contact points between LD and other cellular compartments. Multiparametric immunofluorescence staining placed the lipid droplets into the T-cell uropod, a migration-enabling cell protrusion typical for activated and polarized T-cells (Figure 2H). RA CD4+T-cells frequently formed a uropod (Figure S3C), in line with their hypermobile state.12 LD were almost exclusively localized near the uropodal PM. LD-PM distances were 300–400 nm in healthy cells but shrank to <20 nm in RA CD4+T-cells (Fig.2I-J). Often, LD aligned like a “string of pearls” along the inner and outer PM face. Lipid stress, imposed by treating CD4+T-cells with exogenous OAc, rapidly moved LD to the PM and induced integration of PLIN2 into the membrane. We confirmed direct LD-PM contact by isolating cell membranes of lipid-stressed CD4+T-cells (marker molecules CD3 and CD44) and probing with anti-PLIN2 antibodies to demonstrate incorporation of the LD protein into the PM (Figure 2K-L).
Together, these data suggested that mitochondrial deficiency in RA CD4+T-cells restructure subcellular organelles (ER membrane extension, LD formation) and redistribute LD toward the PM.
FFA-rich tissues are detrimental to metabolically exhausted T cells.
Prompted by data demonstrating FFA enrichment in both the inflamed synovial tissue and tissue-residing CD4+T-cells, we examined how FFAs regulate T-cell survival and function and whether they shift T-cells towards pathogenic effector functions. We collected CD4+T-cells from the peripheral blood of healthy controls and patients with RA, and synovial tissue from patients with RA. We exposed all CD4+T-cells to lipid stress, tracked their response using live cell imaging and quantified cell death (Figure 3A-B). Given the enrichment of OAc in RA LD, we treated T cells with OAc. Healthy CD4+T-cells contained few LDs and survived the lipid challenge (Figure 3C). Circulating RA CD4+T-cells carried small LDs and were predisposed to death. OAc treatment induced PM disintegration, accelerated death rates. CD4+T-cells from RA tissue were packed with large, confluent LDs and highly susceptible to lipid-stress, with only a fraction still alive after 1h (Figure 3C-D). Lipid-exposed cells underwent cellular swelling and complete PM fragmentation (Figure S4A). Imaging studies suggested that LD were integrated into the plasma membrane before being expelled into the extracellular space (Figure 3E-F). T-cell death induction was dose-dependent (Figure S4B).
Figure 3. Fatty acids induce plasma membrane damage in CD4+T-cells.

Peripheral blood CD4+CD45RO−T-cells from controls and RA patients were stimulated for 72h. Tissue CD4+T-cells derived from digested RA synovial tissue biopsies. T-cells were treated with vehicle or OAc (10μg/mL) for 30 and 60 minutes.
(A-B) Quantification of CD4+T-cell survival after OAc treatment. Cell viability measured by trypan blue exclusion or LDH leakage. Dashed lines represent average control levels. Data from 8–12 experiments.
(C) Cellular response patterns to OAc treatment analyzed by confocal live-cell imaging. Plasma membranes (WGA;red); LDs (BODIPY493/503;green); nuclei (Hoechst-33342;blue) (n=12/group). Scale bar; 5μm.
(D) OAc-induced lipid loading quantified by BODIPY493/503 staining. 30 cells analyzed/sample (n=6/group).
(E) Live-cell image of RA CD4+T-cells treated with OAc (10μg/mL) for 6h. Dashed lines mark cell boundaries. Representative data from 6 experiments. Scale bar; 5μm.
(F) Intensity of BODIPY493/503/Hoechst-33342 and cell sizes were calculated. 30 cells analyzed/sample (n=6/group).
Mean ± SEM with individual data points shown. Control vs treatment: paired student t test (A,B); Control PBMC vs RA PBMC and RA synovial tissue: Unpaired student t test adjusted for multiple comparison using Holm-Šídák method (A,B). Unpaired student t test (D,F).
These results supported the concept that LD-bearing CD4+T-cells are at risk for membrane pore formation and cell death, enabling FFA-rich tissues to transform invading T-cells into inflammation inducers.
RA CD4+T-cells sequester the pore-forming molecule gasdermin D in LD.
LD ejection from the T-cell uropod and membrane disintegration elicited by exogenous lipids pointed to the possibility of LD inducing lytic cell death. We isolated LD from healthy and RA CD4+T-cells and proceeded with mass spectrometry-based proteomics (Figure S5A-B). LD derived from control, fatty acid-loaded control and RA CD4+T-cells displayed distinguishing protein profiles, with RA disease state and lipid-loading resulting in coordinated upregulation of proteins (Figure 4A-B, Table S1). LDs from RA and fatty acid-stressed T cells shared the enrichment of proteins involved in LD structural support, fatty acid metabolism, and lipid transport (PLIN2, FASN, PGRMC1). A group of enriched proteins (ECI1, DECR1, CLUH, HADHA/HADHB) typically associated with LD-mitochondria contact sites indicated high mitochondrial stress in both RA and FFA-exposed T cells. Accumulation of the palmitoyl-protein hydrolase LYPLA2 pointed towards possible LD engagement in membrane lipid modifications. Finally, the increased representation of GSDMD and its activating protease, caspase 1 (CASP1)-both key mediators of inflammasome induced membrane pore formation-suggested a potential crosstalk between lipid metabolism and inflammatory cell death pathways. Table S1. Pathway enrichment analysis of RA LD-enriched proteins yielded a strong association with fatty acid metabolism, inflammasome activity, oxidative stress, mTORC1 signaling, and exosomal pathways (Figure S5C).
Figure 4. LD in RA CD4+T-cells sequester the pore-forming molecule Gasdermin D.

CD4+CD45RO−T-cells from patients with RA or PsA and from age-matched controls were stimulated for 72h.
(A) LD were isolated from healthy and RA CD4+T-cells and subjected to proteomics analysis (n=3 each). Volcano plot presentation of differentially expressed LD-associated proteins. Vertical dashed lines represent fold-change cutoffs; log2, the horizontal line indicates the p-value threshold (Cutoff, p=0.05).
(B) Illustration of LD proteins based on proteomic analysis.
(C-E) Quantification of PLIN2 expression in CD4+T-cells.
(C) Flow cytometric analysis of PLIN2 in CD4+T-cells (n=6/group).
(D) Representatives immunoblot of PLIN2 in control, RA and PsA CD4+T-cells (n=3/group).
(E) Representative immunofluorescence images of PLIN2 and BODIPY493/503 in control, RA and PsA CD4+T-cells. Scale bar; 10μm. (n=6/group).
(F) PLIN2 mRNA (RT-PCR) in CD4+T-cells from controls and patients with RA, PsA, SLE, and GPA. n=6/group).
(G) Immunoblot of PLIN2 and GSDMD in control and RA LDs. Loading control; PLIN3. Bar graphs show band intensities.
(H) Heatmap of GSDMD mRNA transcript from control and RA (n=10/group)
(I) Immunoblot of GSDMD-F and the active fragment GSDMD-N in control and RA CD4+T-cells. Band intensities shown as bar graphs (n=6/group).
(J) Representative images showing colocalization of GSDMD and LDs. Scale bar;5μm.
Data are mean±SEM with individual data points shown. One-way ANOVA with Dunnett’s multiple comparisons (C,F,G). Multiple t-tests with Two-stage step-up (H,I).
The structural protein PLIN2 is embedded into the LD membrane and protects LD from autophagy.31 We confirmed that high expression of PLIN2 distinguished RA CD4+T-cells from healthy and disease-control T-cells (Figure 4C-E, Figure S5D). PLIN2 mRNA quantification in CD4+T-cells from patients with 4 autoimmune diseases (RA, PsA, systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA) excluded systemic inflammation as the sole driver of PLIN2 upregulation (Figure 4F). In RA CD4+T-cells, PLIN1 and PLIN2 mRNA levels were spontaneously elevated (Figure S5E) compatible with a poised state for FFA accumulation and LD building.
To validate the GSDMD’s integration into LD, we compared expression of PLIN2 and GSDMD in purified LDs. PLIN3 served as loading control.32 Immunoblotting confirmed that RA LD carried 2-fold higher amounts of PLIN2 and consistently contained GSDMD, while GSDMD was undetectable in healthy LD (Figure 4G). Caspase-dependent GSDMD cleavage releases an active GSDMD-N-terminal p30 fragment that oligomerizes and forms PM pores.33 Transcriptomic analysis and immunoblotting documented spontaneous upregulation of GSDMD exclusively in RA CD4+T-cells (Figure 4H-I). Immunofluorescence staining localized GSDMD to the uropod of RA CD4+T-cells, where it co-localized with BODIPY+-LD (Figure 4J). The protein remained undetectable in healthy CD4+T-cells.
In essence, RA CD4+T-cells are primed to form specialized LD, which transports the pore-forming molecule GSDMD.
Lipid droplet-rich CD4+T-cells die by pyroptosis.
Next, we examined whether GSDMD sequestration into LD has a role in lipid-induced T-cell death. GSDMD-dependent cell death requires cleavage of auto-inhibited GSDMD and generation of active N-terminal fragments, which oligomerize into large membrane pores.34 Lipid-induced cell body swelling and release of intact LD (Figure 3E) strongly suggested lytic death of RA CD4+T-cells, instead of anti-inflammatory.35 Live cell imaging of tissue-derived RA CD4+T-cells showed ejection of intact nuclei (Figure 5A), a process aggravated by OAc. Supernatants from RA but not healthy CD4+T-cells contained nuclear DNA and PLIN2 protein (Figure 5B, Figure S6A). OAc-induced lipid stress imposed rapid PM disintegration in patient-derived T-cells, which breached their cell membrane and became SYTOX positive (Figure 5C-D). Lipid treatment consistently increased LDH leakage and cell death (Figure S6B). Together these morphologic changes supported a lytic and inflammatory cell death mode of LD-loaded T-cells.
Figure 5. Fatty acids induce pyroptotic T-cell death.

(A) BODIPY493/503 staining of CD4+T-cells isolated from synovial tissue biopsies. Plasma membranes (PM) marked with wheat germ agglutinin (red) and nuclei with DAPI. Scale bar;5μm.
(B) Control and RA CD4+T-cells were activated for 72h and treated with OAc for 1h. Immunoblot analysis of supernatants for nuclear DNA (ncDNA), β2-microglobulin (B2M), D-Loop amplified DNA and free PLIN2. Representative blots from 3 experiments.
(C) Representative live-cell images showing SYTOX-Green uptake in CD4+ T-cells from healthy controls, RA, and PsA (n=6/group). Scale bar:20μm.
(D) Representative live-cell images showing SYTOX-Green uptake in CD4+ T-cells treated with OAc (10μg/mL, 6h) (n=6/group). Scale bar:20μm.
(E) Control CD4+T-cells were treated with Oleic acid (0, 10, 25μg/mL) or Palmitic acid (0, 1, 2, 5μM) for 6h. Heatmap of mean relative mRNAs from three experiments.
(F) Control and RA CD4+T-cells were stimulated for 72h. Supernatants were analyzed for CASP1, IL-1β, and IL-18. Cell lysates were analyzed for PLIN2, NLRP3, PLIN3, CASP1, GSDMD, and β-actin. Representative immunoblots from 3 experiments.
(G) Control CD4+T-cells were treated with vehicle or OAc (10μg/ml, 6h). Supernatants were analyzed for CASP1, IL-1β, and IL-18. Cell lysates were analyzed for PLIN2, NLRP3, PLIN3, CASP1, GSDMD, and β-actin. Representative immunoblots from 4 experiments.
GSDMD cleavage requires activation of upstream sensors and caspases (CASP). We pursued a molecular definition of lipid-induced cell death based on gene induction elicited by stressing CD4+T-cells with OAc and palmitic acid (PA). CD4+T-cells responded to both fatty acids by regulating a similar gene signature: PLIN2, NLRP3, CASP1, GSDMD, IL-1b and IL-18 (Figure 5F). Immunoblot analysis of cell supernatants detected the release of cleaved CASP1, IL-1β, and IL-18 in RA and lipid-stressed CD4+T-cells (Figure 5G). Lipid treatment enhanced NLRP3, CASP1 and GSDMD protein expression, and cell lysates had a signal for GSDMD-N, all supporting pyroptosis as the relevant cell death (Figure 5G). Plasma samples from patients with RA contained elevated levels of IL-1β, compatible with continuous CASP1 activation (Figure S6C). Lack of CASP3/7/8 cleavage ruled out apoptosis and PANoptosis36 (Figure S6D).
Lipid stress did not upregulate ferroptosis-related genes (Figure S7A), in line with the accumulation of reduced but not oxidized FFA in RA CD4+T-cells (Figure 2A-C). In support, pretreatment of RA CD4+T-cells with the ferroptosis inhibitors, Ferrostatin-1 and Liproxstatin-1, did not protect from lytic cell death (Figure S7B-E).
Accordingly, extracellular lipids emerge as inducers of pyroptosis, and RA CD4+T-cells are primed to respond to FFA with pyroptotic cell death.
Lipid droplets in RA CD4+T-cells absorb the acyltransferase zDHHC5.
GSDMD sequestration into LD shifted the function of these organelles from lipid storage vesicles to membrane pore inducers, provided that GSDMD is released from its self-inhibited state. Membrane pore formation involves caspase-dependent cleavage, liberation of GSDMD-N, and assembly into large transmembrane channels, achieved by partnering GSDMD with fatty acid synthase and acyltransferase-dependent S-acylation.37,38 In RA CD4+T-cells, GSDMD-loaded LD redistributed to the inner PM face (Figure 2I-J) and formed direct contact points. To pursue the hypothesis that GSDMD could be activated within the LD, we identified relevant S-acylases and investigated whether specific members of the zDHHC family facilitated LD-induced membrane injury in T-cells. In a focused expression screen of 22 zDHHC genes, zDHHC5, zDHHC17, and zDHHC20 were significantly upregulated in RA T-cells (Figure 6A). Previous reports have assigned zDHHC5 and zDHHC20 as primarily PM located39,40, identifying them as candidate PATs in GSDMD lipidation (Figure 6B). Silencing of zDHHC5 or the KD-zDHHC5/KD-zDHHC20 combination in lipid-stressed RA CD4+T-cells significantly reduced SYTOX uptake and LDH leakage (Figure 6C-E). zDHHC5 knockdown attenuated the extracellular release of LD and of nuclear DNA (Figure 6F-G). These data placed zDHHC5-mediated S-acylation upstream of LD-dependent membrane disintegration and the spread of inflammatory materials into the tissue space.
Figure 6. Lipid droplets from RA CD4+T-cells transport the acyltransferase zDHHC5.

CD4+CD45RO−T-cells from controls and RA patients were stimulated for 72h.
(A) Relative mRNAs of hzDHHCs in control and RA CD4+T-cells (n=6/group)
(B) Predicted subcellular localization of hzDHHC enzymes summarized in a Venn diagram39,60.
(C-G) RA CD4+T-cells were transfected with con_siRNA, hzDHHC5_siRNA, hzDHHC20_siRNA, or both and treated with vehicle or OAc for 6h.
(C) Live-cell images for SYTOX-Green uptake. (n=6/group). Scale bar; 100 μm.
(D) Quantification of SYTOX+T-cells (n=6 experiments).
(E) Quantification of LDH leakage after treatment with vehicle or OAc for 6h. (n=6/group).
(F) Supernatants were analyzed on agarose gels and native-PCR (β2-microglobulin for nuclear DNA and D-Loop for mitochondrial DNA) (n=2/group).
(G) Representative immunoblotting of supernatants for released PLIN2 (n=2/group).
(H) PM and LD fractions were isolated and immunoblotted for zDHHC5, PLIN2, CD3, and β-actin. Two samples/group from 3 experiments.
(I) Immunofluorescence staining of hzDHHC5 and BODIPY in control and RA CD4+T-cells. Scale bar; 10μm.
(J) PLIN2 was immunoprecipitated from vehicle and OAc-treated RA CD4+T-cells. Precipitates were immunoblotted for zDHHC5. One of 3 experiments shown.
All data are mean ± SEM with individual values shown. One-way ANOVA and Dunnett’s multiple comparisons test (D,E).
To understand GSDMD-zDHHC5 interactions in LD-dependent membrane damage, LD ejection, and DNA release, we mapped the subcellular positioning of the enzyme. Immunoblot analysis of isolated LD and PM fractions verified the enrichment of zDHHC5 and PLIN2 in both the LD and the PM fraction (Figure 6H). RA CD4+T-cells had a stronger signal for zDHHC5 than healthy T-cells, with expression in both the PM and in LDs (Figure 6I). Also, pulldown experiments yielded support for PLIN2-zDHHC5 complex formation in LD isolated from lipid-stressed RA CD4+T-cells (Figure 6J).
Taken together, these findings identified zDHHC5 as a PLIN2 binding partner on the LD membrane coating and implicated the enzyme in GSDMD acylation and plasma membrane poration in lipid-stressed T-cells.
Blocking lipidation in CD4+T-cells protects tissue from inflammation.
To explore the biological relevance of GSDMD lipidation, we examined whether blocking GSDMD acylation prevents tissue inflammation. 2-bromopalmitate (2-BP) and Cyano-myracrylamide (CMA)41,42 are S-acylation pan-inhibitors that block zDHHC-dependent GSDMD modification.34 Treatment with the pan-acylation inhibitors efficiently protected the membrane of lipid-stressed RA CD4+T-cells from damage (Figure S8A-B). To validate the cytoprotective effect in vivo, we treated synovium-engrafted NSG mice with 2-BP or CMA (Figure S8C). Treatment markedly reduced synovial cell infiltration, dead cell accumulation, macrophage and lymphocyte accumulation (Figure 7A-B). Blocking GSDMD acylation sharply suppressed the tissue recruitment of CD4+T-cells, and of IFN-γ– and TNF-producing T-cells. Restraining S-acylation diminished CD68+ macrophage infiltration, including TNF- and IL-6-producing macrophages. Cytoprotective and anti-inflammatory effects of 2-BP and CMA extended to the synovial stromal cell population, where frequencies of pro-inflammatory IL-6+FAP+ fibroblast-like synoviocytes declined (Figure 7C). Inhibition of S-acylation effectively prevented LD deposition in the synovial tissue space (Figure 7D-E) and diminished levels of PLIN2 circulating in the plasma (Figure 7F).
Figure 7. Inhibition of zDHHC5-mediated palmitoylation or blocking lipid droplet formation in CD4+T cells abrogates synovial tissue inflammation.

(A-F) NSG mice engrafted with human synovium were immunoreconstituted with PBMC from RA patients. Chimeras were treated intraperitoneally with vehicle, 2-bromopalmitate (2-BP; 20 mg/kg), or cyano-myracrylamide (CMA; 20 mg/kg) for one week. Synovial grafts were collected for histology and flow cytometry. Each group included eight tissues.
(A) H&E images of synovial explants from vehicle, 2-BP and CMA-treated chimeric mice. Scale bar; 50μm.
(B) Histomorphometric analysis of explanted synovial tissues. Cell populations were quantified by digital analysis of H&E-stained images. Each dot represents an individual high-power field.
(C) Synovial explants were digested and analyzed by flow cytometry. All numbers are normalized to tissue weight (cells/gram). Frequencies of CD4+T-cells, IFN-γ+CD4+T-cells, TNF+CD4+T-cells, CD68+ macrophages, TNF+CD68+macrophages, IL-6+CD68+macrophages, FAP+synovial fibroblasts and IL-6+FAP+fibroblasts are presented as heatmap. Each lane represents one tissue.
(D-E) Synovial tissue sections were stained with BODIPY493/503. Membranes were marked with WGA and nuclei with DAPI. Scale bar;20μm. BODIPY493/503 intensity was quantified.
(F) Immunoblot of human PLIN2 in mouse plasma; Loading control; Ponceau S. Data from 2 mice are shown.
(G-N) NSG mice engrafted with human synovial tissue were randomly assigned to four study arms. Control CD4+CD45RO−T-cells were transfected with either a control plasmid (arm-1) or PLIN2 plasmid (arm-2) (G-J). RA CD4+CD45RO−T-cells were transfected with either control siRNA (arm-3) or PLIN2 siRNA (arm-4) (K-N). Transfected T-cells were adoptively transferred into the tissue-engrafted mice. Each arm included six tissues. Explanted synovial grafts were analyzed by flow cytometry, RT-PCR, and immunohistochemistry.
(G) H&E images from synovial explants.
(H-I) Frequencies of lymphocytes, macrophages, stromal cells and dead cells were measured by histomorphometry. Frequencies of tissue-infiltrating CD3+T-cells, BODIPY+CD3+T-cells, IFN-γ+CD3+T cells, T-bet+CD3+T-cells, and RORγτ+CD3+T-cells were determined by flow cytometry. Data presented as heatmap.
(J) Immunofluorescence staining of tissue sections for BODIPY493/503, IFN-γ and CD3+T-cells.
(K) H&E images from synovial explants.
(L-M) Frequencies of lymphocytes, macrophages, stromal cells and dead cells quantified by histomorphometric analysis. Frequencies of tissue-infiltrating CD3+ lymphocytes, BODIPY+CD3+T-cells, IFN-γ+CD3+T cells, T-bet+CD3+T-cells, and RORγτ+CD3+T-cells measured by flow cytometry. Data presented as heatmap with each lane representing one tissue.
(N) Synovial tissue sections stained for BODIPY493/503, IFN-γ and CD3+T-cells.
All data are mean ± SEM with individual values shown. One-way ANOVA and Dunnett’s multiple comparisons test (B,C,F). Two-tailed, unpaired Mann-Whitney-Wilcoxon rank test (H,I,L,M). Scale bars; 50 μm.
These proof-of-principle treatment trials endorsed the concept that S-acylation is a critical checkpoint in LD biogenesis and LD-induced membrane damage, with zDHHC5 functioning as a key mediator of lipid-induced membrane poration.
LD are pro-inflammatory organelles in rheumatoid synovitis.
Above findings classified LD as potentially inflammatory organelles, inflicting membrane damage and pyroptotic T-cell death. We pursued the question whether LD per se represent therapeutic targets and whether the suppression of LD formation in CD4+T-cells protects synovial tissue from inflammatory attack. To modulate lipid droplet abundance in T-cells, we targeted PLIN2, a critical LD structural protein.43
We either increased or decreased PLIN2 expression selectively in purified CD4+T-cells, transferred them into tissue-engrafted NSG chimeras (Figure S9A-B), and then examined the intensity of synovial tissue inflammation. PLIN2 overexpression (PLIN2-OE) resulted in: (1) Higher density of inflammatory cell infiltrates (Figure 7G); (2) accumulation of dysmorphic nuclei indicating cell death (Figure 7H); (3) higher frequencies of CD3+T-cells, specifically, IFN-γ-producing T-cells, BODIPY+(LD-containing)-T-cells, and T-bet+ CD4+T-cells (Figure 7I); (4) higher expression of inflammatory cytokine genes (IL-1β, IFN-γ, TNF, IL-6, IL-17A); (5) higher expression of T-cell lineage-determining transcription factors (TBx21; RORC) (Figure S9C); and (6) diffuse deposition of BODIPY+ -LD in the extracellular space (Figure 7J).
Conversely, we knocked down PLIN2 selectively in CD4+T-cells (Figure S9D-H). Mice receiving PLIN2-silenced CD4+T-cells displayed markedly reduced synovial tissue inflammation, with significantly fewer dead cells, BODIPY+CD3+T-cells, CD3+-IFN-γ+ and CD3+T-bet+−T-cells. Transfer of PLIN2-deficient CD4+T-cells quickly lowered the LD deposits in the tissue (Figure 7K-N).
In vitro experiments validated that PLIN2-OE had profound impact on the lineage commitment of CD4+T-cells and was sufficient to turn them into pro-inflammatory effector cells. PLIN2hi-expressing CD4+T-cells responded to lipid exposure with rapid differentiation into T-bet+ and RORγt+T-cells that were committed to the production of inflammatory cytokines, including IFN-γ, IL-17 and IL-21 (Figure S10A-F).
These results identified LD in T-cells as pro-inflammatory organelles and demonstrated their therapeutic targetability in autoimmune tissue inflammation.
DISCUSSION
Traditional paradigms have focused on autoantigens as key factors in autoimmune disease, linking pathogenic T-cell function to antigen specificity. However, current data challenge this notion, showing that CD4+T-cells can instigate tissue inflammation through pyroptosis, releasing danger-associated molecular patterns (DAMP). Underlying mechanisms connect the metabolic constraints in nutrient-stressed tissues to T-cell stress responses and to pro-inflammatory, lytic cell death. We reveal a novel pathway where CD4+T-cells in the lipid-rich rheumatoid joint form LDs that sequester the pore-forming molecule GSDMD and its zDHHC5 S-acylase. Under lipid stress, GSDMD+zDHHC5+ LDs move to the PM and create membrane pores, releasing nuclear and cytosolic content, including intact LDs that promote continued lipid accumulation at inflammatory sites. Our data show that RA CD4+T-cells are primed to support this disease mechanism due to their metabolic conditioning that includes severe mitochondrial impairment, suppressed lipolysis, and enhanced LD formation. In humanized mice, inhibiting LD formation or blocking global S-acylation in RA CD4+T-cells is sufficient to reduce synovitis (Figure 7). Conversely, enforcing LD formation in healthy CD4+T-cells transforms these T-cells into tissue-damaging effector cells and effectively breaks tissue tolerance, highlighting this metabolic pathway as a crucial checkpoint in autoimmune disease.
Classically, LD are recognized as cytosolic fat storage organelles that supply lipids based on bioenergetic needs.17,19,43–45 Data presented here redefine the role of LD in CD4+T-cells, revealing that LD act as pro-death-organelles that move to the PM and cause membrane leakage and lytic cell death. This transformation from protective to damage-inducing organelles requires a change in the LD proteome. Specifically, the sequestration of GSDMD and zDHHC5 to GSDMD+zDHHC5+ LD, which become key compartments linking lipid metabolism abnormalities and pyroptotic T-cell death to synovitis.
The shift in the LD proteome occurs in RA CD4+T-cells which have reconfigured their bioenergetic networks and have entered a state of pseudo-starvation. Due to mitochondrial DNA repair defects3, they exhibit low mitochondrial fitness with diminished ATP and NAD production.15,46 These T-cells adapt by downregulating glycolysis and redirecting glucose into the pentose-phosphate pathway15,47, resulting in elevated NADPH and intensified lipogenesis.46 A lack of mitochondrial beta-oxidation further drives lipid synthesis12, and boosts cytosolic acetyl-CoA and citrate levels.15 Low ATP and NAD+ suggest that RA CD4+T-cells are in starvation mode, barely able to meet bioenergetic and biosynthetic needs. Prior studies indicate that this pseudo-starvation mode48 affects most RA T-cells48, broadly impacting the immune system beyond rare antigen-specific T-cells.13 The cause of this metabolic transformation in RA CD4+ T-cells is unexplained but renders this cell population susceptible to non-canonical functions, such as membrane lysis and DAMP release, which may be particularly relevant in disease chronicity.
Mitochondrial failure and pseudo-starvation trigger cellular stress responses.10,48,49 Accordingly, RA CD4+T-cells exhibit lysosomal deficiencies50,51 and are under ER stress.4,14 ER stress responses involve remodeling lipid metabolism, storing lipids in LDs, and preparing cells for high metabolic demands.45,52,53 TCR stimulation of RA CD4+T-cells induces ER stress and formation of large LDs, as these cells anticipate clonal expansion with high bioenergetic and biosynthetic demands. CD4+T-cells from inflamed joints displayed the highest susceptibility to LD-dependent cell lysis, suggesting a state of metabolic burnout. Both joint-derived and circulating-RA CD4+T-cells upregulated PLIN2 and accumulated LD, placing the metabolic adaptations prior to these cells entering disease lesions. Inflammasome activation upstream of GSDMD activation is frequent in lymph node T-cells of patients with RA3,11, suggesting that lymphoid tissues prime RA CD4+T-cells for low metabolic resilience.
Chronic inflammation sites, like the tumor microenvironment, represent nutrient-stressed niches.54 RA CD4+T-cells face challenging metabolic conditions when infiltrating glucose-deplete synovial tissue.9 Educated under conditions of poor mitochondrial performance, these T-cells become less reliant on glucose, gaining a survival advantage in the synovial space. Targeted metabolomics have revealed high levels of glutamine in RA synovium.9 However, glutaminolysis requires a functional TCA cycle, which is compromised in RA CD4+T-cells, forcing them to depend on FFAs for energy. Given that high FFA concentrations are typical in atherosclerotic lesions, T-cells may experience similar nutrient stress within atherosclerotic plaques, which may explain the increased cardiovascular risk in RA.55
While the role of metabolites in DNA and histone acetylation and methylation links nutrient supply with epigenetic regulation, data presented here deepens understanding of how metabolites regulate posttranslational protein modifications.38 Notably, RA CD4+T-cells exhibit defects in protein N-myristylation50. The current study identifies protein palmitoylation as a critical checkpoint for T-cell differentiation and membrane integrity. The cleavage of the pore-forming molecule GSDMD requires S-acylation, with FASN providing the substrate needed in this modification.38 An S-acylase positioned upstream of GSDMD activation indicates that membrane pore formation occurs preferentially in lipid-rich environments, like the rheumatoid joint, underscoring how tissue nutrient availability dictates T-cell functionality.
Current data emphasize that LD formation is host-damaging, precisely, by inducing tissue inflammation. Genetic polymorphisms linked to RA susceptibility reside in genes vital for CD4+T-cell function. Traditional effector functions include cytokine production, help for autoantibody-producing B-cells, and T-cell cytotoxicity. Current insights expand pathogenic T-cell functions to include lytic cell death. While T-cells typically die via anti-inflammatory apoptosis, lipid-induced pore formation leads to cell lysis and release of DAMP. T-cell supernatants contained nuclear and cytosolic contents, including nuclear DNA and PLIN2. OAc and palmitic acid upregulated a gene signature linked to inflammasome components, inflammatory caspases, IL-1, and IL-18, all characteristics of pyroptosis. These findings support a model where tissue-residing T-cells, under lipid stress and lacking metabolic plasticity, undergo pyroptosis instead of apoptosis. This shift has significant implications; while apoptotic T-cells are quietly cleared, pyroptotic T-cells release immunogenic DAMPs, including mitochondrial and nuclear DNA, perpetuating synovial inflammation even without antigenic stimulation. Therefore, T-cell pyroptosis may be a key mechanism underlying the self-sustaining nature of rheumatoid synovitis.
One surprising finding in this study is LD-based sequestration of GSDMD. Through proteomic analysis, immunoblotting, and immunofluorescence, we showed that GSDMD is enriched in the LD fraction and colocalizes with PLIN2 in the T-cell uropod. Upon lipid stress, GSDMD+LD translocated to the PM, promoting pore formation. RA CD4+T-cells also co-packaged zDHHC5 into the LD, with functional assays confirming the cytoprotective effects of inhibiting S-acylation in-vitro and in-vivo. Normally, GSDMD and the lipidating enzyme are kept in separate compartments (cytosol and PM), preventing spontaneous GSDMD activation. However, lipid-induced cellular stress disrupts this protective mechanism, leading to membrane translocation of GSDMD+zDHHC5+LD and LD release into the extracellular space. Conceivably, GSDMD+zDHHC5+LD could provide an outlet for excess lipids being expelled from the cell. In the rheumatoid joint, possibly due to high FFA concentrations, safe release of LDs is replaced by membrane disintegration, contaminating the tissue with ever-growing FFA deposits and sustaining a feed-forward loop of tissue inflammation.
Paradoxically, inflammation-inducing LD were enriched for OAc, a monounsaturated fatty acid often classified as a “healthy fat”.56,57 The effect of OAc and palmitic acid in inducing lytic T-cell death was indistinguishable, suggesting that all FFAs are potentially pathogenic, if the absorbing T-cell fails to catabolize lipids and utilize them for enhanced functionality. Patients with RA are at substantial risk for cardiovascular complications and intriguingly, OAc is also a significant component of the FFA profile in atherosclerotic plaque58,59, pointing towards shared lipid-induced pathomechanisms in RA and atherosclerosis.
In conclusion, our data define a novel, metabolically controlled mechanism of inflammatory cell death in RA CD4+T-cells. Metabolic pre-conditioning leads to the accumulation of LDs that integrate into the PM to facilitate GSDMD-dependent pyroptosis. This process is ultimately regulated by zDHHC5, which enables membrane-near GSDMD activation and acts as a bridge between abnormal lipid handling and pro-inflammatory cell death.
Current RA therapies mainly focus on cytokine inhibition and general immunosuppression, but our findings suggest a new therapeutic approach, restoring metabolic resilience or blocking lipid-triggered pyroptosis in tissue-residing T-cells. We demonstrate that genetic and pharmacological inhibition of PLIN2 or zDHHC5 significantly reduces inflammation in-vivo. Notably, treatment with 2-BP or CMA, both broad-spectrum S-acylation inhibitors, preserved PM integrity, reduced DAMP release, and suppressed immune cell infiltration into synovial tissue without depleting T-cells or impairing antigen recognition, indicating a selective anti-inflammatory mechanism. The importance of LD and zDHHC5 in this pathway may also lead to biomarker development; high expression of PLIN2, GSDMD, CASP-1, or zDHHC5 in circulating T-cells could identify patients at risk for severe disease or poor response to conventional therapies. Targeting lipid metabolism or specific S-acylation inhibitors may effectively protect vulnerable immune cells from lytic death and provide treatment for challenging RA cases.
Limitations of the study
While our model establishes a causal link between altered lipid metabolism, lytic T-cell death, and sustained tissue inflammation, several questions remain. First, the upstream triggers for the upregulation of PLIN2, GSDMD, and zDHHC5 in RA CD4+T-cells, required for the priming of these cells, need further investigation. Although fatty acid exposure may induce these genes, the mechanisms by which cells recognize extracellular lipids, adapt their lipid metabolism and organelle function and do so over decades, all remain undefined.
Second, the broader relevance of this pathway to other T-cell subsets and autoimmune contexts is unknown. Similar mechanisms might operate in CD8+T-cells, regulatory T-cells, or tissue-resident memory cells within lipid-rich tissues (e.g., adipose tissue, liver, CNS). Exploring whether LD-GSDMD interactions influence T-cell fate in obesity-related inflammation or neuroinflammation will be an important next step.
Finally, while our in-vivo model recapitulates essential features of human synovitis, future studies using spatial transcriptomics or single-cell proteomics could yield deeper insights into the tissue microenvironment and identify additional metabolic checkpoints that regulate tissue inflammation.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to cweyand@stanford.edu
Materials availability
Mouse strains and plasmids are available upon request.
Data and code availability
Source data and original blots are included in Data S1. This manuscript did not generate new code.
STAR★METHODS
EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS
Patients
Patients enrolled in the study fulfilled 2010 ACR diagnostic criteria for RA and were positive for rheumatoid factor and/or anti-CCP antibodies. All patients with RA (n=173) recruited had active disease. Individuals with a current or previous diagnosis of cancer, uncontrolled medical disease or non-rheumatic chronic inflammatory syndrome were excluded from enrollment. Patients with a diagnosis of PsA (n=33; age: 59.0 ± 9.2 years; 41.2% females), Systemic Lupus Erythematosus (SLE) (n=6), and Granulomatosis with Polyangiitis (GPA) (n=6) served as disease controls. Demographic and clinical characteristics of RA and PsA patient populations are summarized in Supplementary Table 2. Healthy age-matched individuals without a personal history of cancer or autoimmune disease were recruited from the Blood Bank of Mayo Clinic Rochester (n=96). All patients and controls provided informed consent and did not receive compensation. All studies were approved by the Institutional Review Board (IRB) at the Mayo Clinic, Rochester, MN, USA-55902.
Synovial tissue samples
The Institutional Review Board of the Mayo Clinic, Rochester, MN 55902, USA, approved the study and all patients signed informed consent. Synovial tissue samples were collected from synovectomies or total joint replacement surgeries, mostly from patients with refractory RA. Approximately 15% of patients diagnosed with RA have persistent, treatment-refractory inflammation that fails to respond to multiple disease-modifying therapies. These patients continue to have active joint inflammation over years and decades61,62. Classified as having difficult-to-treat RA (D2T-RA), these patients provided an important model system for investigating chronic synovial inflammation. All tissue samples derived from the knee joints of patients with active disease. Active disease was defined as the presence of ≥6 swollen or tender joints and levels of at least moderate on the physician’s and patient’s assessments of disease activity. Patients on prednisone higher than 10 mg/day were excluded. Steroid injections into the knee joint in the last 90 days were considered an exclusion criteria for tissue collection. Tissues were assessed for synovial hyperplasia, vascularization, and density of the cellular infiltrate before they were selected for further experiments. Non-inflammatory control tissues derived from individuals with mechanical joint injuries.
Synovial tissue histopathology and synovitis scoring.
All tissue samples underwent histopathological evaluation to confirm the absence or presence of synovitis, and the intensity of synovitis was graded. Serial tissue sections (5 μm) spanning a total of 500 μm3 of tissue were stained with hematoxylin and eosin (H&E). At least two individuals who had undergone training in the histomorphology assessment of synovial tissue provided a score from 2–5 sections (localized 100 μm apart) to create a single grade for each histopathological feature. We used the criteria set by Krenn and colleagues63 and Najm et al with slight modifications64 to provide uniform synovitis scoring for all tissues enrolled into the study. The composite synovitis score included four major parameters to semi-quantitatively classify the degree of synovial inflammation: 1) synovial lining thickness, 2) density of sub-synovial lymphocytic and plasma cell inflammatory cell infiltrate, 3) activation of stromal elements including multinucleated giant cells, and 4) sub-synovial neovascularization. Finally, scores for each histopathological feature were averaged across the number of sections per sample. In the composite inflammation score, median grades for each component were combined and each patient fell into one of the following categories: category 1, none/normal, average grade <2.0; category 2, mild, average grade 2.0 to 6.0; category 3, moderate/severe, average grade >6.0.
Human-chimeric NSG mice
NSG-mice obtained from Jackson Laboratory and maintained in specific pathogen-free conditions at 20–22 °C and on a 12-hour light/dark cycle. All mice had free access to water and standard rodent diet. The synovial tissues were allocated to experiments based on their arrival order in the laboratory. As previously described, 12,46,65 pieces of human synovial tissue were subcutaneously implanted in 8–12-week-old mice. Seven days later, chimeras were reconstituted with healthy or RA PBMC (15 million/mouse) as per experiment requirements. Littermates (both males and females) were used for each independent experiment and randomly assigned to the different experimental groups.
In a series of experiments to evaluate the effect of oleic acid on tissue inflammation, mice reconstituted with healthy PBMC were treated with either vehicle or oleic acid (10 mg/kg body weight). CD4+ T cells were isolated using MojoSort Human CD4+ T Cell Isolation Kits (BioLegend, #480130), transfected with PLIN2 overexpression plasmids or control plasmids, and then remixed with CD4+ T cell-depleted PBMCs before being adoptively transferred into the mice. In other experiments, RA CD4+ T cells were transfected with siRNA targeting PLIN2 or control siRNA, remixed with CD4+ T cell-depleted PBMCs, and adoptively transferred into the mice. Finally, mice reconstituted with RA PBMCs were treated with either vehicle or 2-BP (2-Bromo-Palmitate, 20 mg/kg body weight) or cyano-myracrylamide (CMA, 20 mg/kg body weight) on alternative days for 8 days. At the end of the experiment, synovial tissues were explanted, OCT-embedded (4583; Sakura Finetek USA) or shock-frozen for further experiments (tissue staining and RNA extraction). To reduce variability introduced by the tissue source and the adoptively transferred immune cells, all mice within one experimental series carried tissue from the same donor patient. All protocols were approved by the Institutional Animal Care and Use Committee of the Mayo Clinic.
METHOD DETAILS
Cells and tissues.
PBMCs were isolated by density gradient centrifugation using Lymphoprep (STEMCELL Technologies). Total human CD4+T cells were isolated from peripheral blood mononuclear cells (PBMCs) using the EasySep™ Human CD4+ T Cell Isolation Kit (STEMCELL Technologies) based on an immunomagnetic negative selection strategy. Briefly, PBMCs were resuspended in EasySep™ buffer and incubated with the supplied antibody isolation cocktail to label non-CD4+ cells, followed by addition of RapidSpheres™ magnetic particles. The labeled unwanted cells were retained using an EasySep™ magnet, while the enriched fraction containing untouched CD4+ T cells was collected, washed, and immediately used for downstream functional and molecular assays.14 To activate CD4+ T cells, they were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum and anti-CD3/anti-CD28 beads (ratio 1:3) for a duration of 3 days before being used in experiments. To assess the responsiveness of CD4+ T cells to free fatty acids, they were treated with vehicle or oleic acid at concentrations of 0, 5, 10, or 25 μg/mL for 24h.
Synovial tissues were obtained from individuals diagnosed with inflammatory polyarthritis undergoing synovectomy or total joint replacement and processed promptly. Fresh synovial tissues were weighed and sliced into thin sections. Single-cell suspensions were prepared by treating with 1 mg/mL collagenase type IV (Worthington, LS004196) and DNase I (100 μg/mL, ZYMO RESEARCH, E1011-A) for 1 hour at 37 °C. Tissue debris was removed using sterile cell strainers (70 μm followed by 40 μm), and CD4+ T cells were isolated using Human CD4 T Cell Isolation kits (BioLegend, #480130 or STEMCELL Technologies).
Fatty acid quantification
Fresh cells or tissues were homogenized, and the free fatty acid (FFA) concentration was measured using the FFA Quantification Kit from Cell Biolabs, Inc. (San Diego, CA), according to the manufacturer’s instructions.
LD fractionation and Lipidomics
Lipid droplets (LD) were isolated from activated CD4+ T cells (~108 cells) using the LD Isolation Kit (Cell Biolabs, MET-5011). After fractionation, the membrane, cytosolic, and LD-enriched fractions were collected for purity assessment. To separate lipids from associated proteins, 1 mL of a chloroform/acetone mixture (1:1, v/v) was added to the LD fraction. Following removal of the organic phase, the remaining pellet was air-dried at room temperature and resuspended in SDS sample buffer for subsequent protein analysis and purity validation.
Lipidomics analysis was performed at the Mayo Clinic Metabolomics Core. LD were extracted with methyl tert-butyl ether (MTBE) and hydrolyzed to release FFAs, which were analyzed by liquid chromatography–tandem mass spectrometry (LC–MS/MS) in negative ion mode. Individual FFAs were identified and quantified using multiple reaction monitoring (MRM) of deprotonated molecular ions, with heptadecanoic acid (C17:0) serving as the internal standard. Fatty acid standards were used to determine absolute concentrations. Samples from healthy and RA LD fractions were adjusted to equal molar amounts of total FFAs. Quantified fatty acids were normalized to the internal standard, expressed as relative percentages of total FFAs, and subsequently transformed into z-scores for comparative representation.
Plasma Membrane fractionation
Healthy and RA CD4+ T cells (1 × 107) were activated with anti-CD3/anti-CD28 Dynabeads for 3 days. Activated healthy CD4+ T cells were then treated with oleic acid at concentrations of 0, 5, 10, or 25 μg/mL for 24h. Following treatment, cells were washed three times with Tris-buffered saline (TBS) and collected by scraping in 1 mL TBS. Cell suspensions were transferred to 50 mL conical tubes and centrifuged to pellet the cells. Membrane and cytosolic fractions were subsequently isolated using the Mem-PER™ Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific, #89842) according to the manufacturer’s instructions. Isolated plasma membrane fractions were subjected to Western blot analysis as indicated.
Acetyl-CoA quantification
The Acetyl-CoA content in the cell-extract was quantified using the Acetyl-CoA Assay Kit (AB87546) (Abcam, MA, USA). The assay was carried out according to the manufacturer’s instructions.
Intracellular ATP Quantification
ATP levels were measured using the ATP Determination Kit (Molecular Probes, Thermo Fisher Scientific, Cat. #A22066), luciferin–luciferase bioluminescence reaction based. Activated CD4+ T cells were lysed in the supplied lysis buffer (20 mM Tris, pH 7.5, 0.1 M NaCl, 2 mM EDTA, and 0.01% Triton X-100). A standard curve covering the nano- to micromolar range (10−9-10−6) was prepared. Equal volumes of reaction solution (luciferase, D-luciferin, Mg2+, and reaction buffer) were added to samples and standards in flat 96-well plates, and luminescence was measured immediately using a Promega GloMax Explorer Multimode Microplate Reader. ATP concentrations were determined by interpolating sample luminescence values from the ATP standard curve.
T Cell Transfections
The Human T Cell Nucleofector Kit (Lonza, Catalog #: VPA-1002) was used to overexpress or knockdown specific genes in T cells. Prior to transfection, CD4+ CD45RA+ T cells were stimulated with anti-CD3/anti-CD28-coated beads and cultured for 3 days to ensure appropriate activation. On day two, the T cells were transfected and rested for 24h to recover from the electroporation. On day four, cells were used for molecular and functional analyses.
Real Time PCR
RNA Extraction and RT–PCR. Total RNA was isolated using TRIzol reagent (Molecular Research Center Inc.) and Direct-zol RNA MiniPrep Kits (Genesee Scientific). cDNA was synthesized from total RNA using ribonuclease H reverse transcription (Invitrogen) and oligo(dT) primers. The primer mix has been tested to generate satisfactory qPCR data on the Quant Studio 6 Pro using the following PCR program: Activation: 50 °C for 2 min, Pre-soak: 95 °C for 10 min, Denaturation: 95 °C for 15 sec, Annealing: 60 °C for 1 min, and Melting curve: 95 °C for 15 sec, 60 °C for 15 sec, 95 °C for 15 sec, performed in triplicate. Expression of individual genes was calculated using a standard curve and normalized to the expression of β-actin. PCR primers used in this study are listed in Supplementary Table 3.
Flow cytometry
Cell surface staining was performed as previously described9,66,67. 4% PFA was used for fixation and 0.1% saponin was used to permeabilize the cells. Samples were analyzed with a CYTEK NL-3000 flow cytometer and data analysis was performed by FlowJo 10.0 (Tree Star). All antibodies used in this study are listed in the above resource table. To detect intracellular cytokines, single-cell suspensions were stimulated with PMA plus ionomycin in the presence of monensin for 5h before being analyzed by flow cytometry.
Immunofluorescence and confocal microscopy
To visualize intracellular and membrane-integrated proteins, previously published methods were applied.14,15 Cells were fixed with 4% paraformaldehyde solution (Affymetrix); unless stated otherwise, primary antibodies were incubated at 4°C overnight, followed by a 1h incubation at room temperature with fluorescence-conjugated secondary antibodies. The primary antibodies used were listed in key resource table. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (Roche). Images were acquired with a LSM980 system (Carl Zeiss), equipped with a Plan Apochromat 63 3 /1.40-NA oil DICIII objective lens (Carl Zeiss). Data were processed using Carl Zeiss software ZEN (blue) and analyzed by ImageJ software.
KEY RESOURCES TABLE.
| REAGENT OR RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| ADFP Antibody (Center), 80uL | Abcepta | #AO1838a; Q99541 |
| Adipophilin / Perilipin-2 Monoclonal Mouse Antibody (ADFP/1365) | Abcepta | # AH13123-20; Q99541 |
| ADRP/Perilipin-2 Monoclonal antibody, 20uL | Protein Tech | # 60340-1-Ig; Q99541 |
| Anti-FLAG® M2 Magnetic Beads | Sigma-Aldrich | #M8823-1ML |
| Anti-Flag-Tag Mouse Monoclonal Antibody 30uL | Booster Bio | # M30971-2-30ul; 17F08 |
| ASC/TMS1 (D2W8U) Rabbit mAb | Cell Signaling Technology | #67824; Q9EPB4 |
| Cytochrome c (D18C7) Rabbit mAb | Cell Signaling Technology | #11940; P99999 |
| Caspase-1 Antibody | Cell Signaling Technology | #2225; P29466 |
| Caspase-1 Cleaved (Asp296) (E2G2I) Rabbit mAb | Cell Signaling Technology | #89332; P29452 |
| Caspase-3 Cleaved (Asp175) (5A1E) Rabbit mAb | Cell Signaling Technology | #9664; P42574 |
| Caspase-7 Cleaved (Asp198) (D6H1) Rabbit mAb | Cell Signaling Technology | #8438; P55210 |
| Caspase-8 Cleaved (Asp374) (18C8) Rabbit mAb | Cell Signaling Technology | #9496; Q14790 |
| CD44 Antibody | Cell Signaling Technology | #3578: P16070 |
| Cleaved Gasdermin D (Asp275) (E7H9G) Rabbit mAb | Cell Signaling Technology | #36425; P57764 |
| Cleaved Gasdermin D (N Terminal) Rabbit mAb | Abclonal | #A24059; 38944952 |
| Cleaved Gasdermin E (N terminal) Rabbit mAb | Abclonal | #A26197; NP_004394.1 |
| FABP1 (D2A3X) XP® Rabbit mAb | Cell Signaling Technology | #13368; P07148 |
| GAPDH (D4C6R) Mouse mAb | Cell Signaling Technology | #97166; P04406 |
| Gasdermin D (E9S1X) Rabbit mAb | Cell Signaling Technology | #39754; Q9D8T2 |
| Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 555 | ThermoFisher | #A-21428 |
| HRP-conjugated β-Actin Rabbit mAb (AC028) 50uL | Abclonal | #AC028 |
| HRP-conjugated Goat anti-Rabbit IgG (H+L) (AS014) | Abclonal | #AS014 |
| HRP-conjugated Goat anti-Mouse IgG (H+L) (AS003) | Abclonal | #AS003 |
| High-Capacity Streptavidin Magnetic Beads (CCT-1497) | Vector Laboratories | #CCT-1497 |
| IL-18 (E8P5O) Rabbit mAb #57058 | Cell Signaling Technology | #57058; P70380 |
| IL-1p Rabbit pAb (A16288) | Abclonal | #A16288 |
| Magne® HaloTag® Beads, 1mL | Promega | #G7281 |
| NLRP3 (D2P5E) Rabbit mAb | Cell Signaling Technology | #13158; Q96P20 |
| PERK (EIF2AK3) Antibody (Center), 80uL | Abcepta | # AP8150c; Q9NZJ5 |
| Perilipin-3 (F8T8T) Rabbit mAb | Cell Signaling Technology | #61336; O60664 |
| SOD1 Antibody (Center), 80uL | Abcepta | #AP8733c; P00441 |
| ZDHHC20 Polyclonal Antibody | ThermoFisher | #PA5-101778; Q5W0Z9 |
| ZDHHC5 (E7T4N) Rabbit mAb | Cell Signaling Technology | #79842; Q9C0B5 |
| Mouse monoclonal anti-CD3 | Dako | #M725401-2 |
| Rabbit polyclonal anti-Interferon gamma | Abcam | #ab25101, RRID:AB_448613 |
| Brilliant Violet 421 anti-human IFN-g | BioLegend | #502532, RRID:AB_2561398 |
| PE anti-human IL-17A | BioLegend | #512306, RRID:AB_961394 |
| Goat anti-rabbit IgG (H+L), Alexa Fluor 488 | ThermoFisher | #A-11008, RRID:AB_143165 |
| Goat anti-mouse IgG (H+L), Alexa Fluor 594 | ThermoFisher | #A-11032, RRID:AB_2534091 |
| Bacterial and virus strains | ||
| MAX Efficiency DH5Alpha Competent Cells | ThermoFisher | #18258012 |
| Chemicals, peptides, and recombinant proteins | ||
| All-in-One Optimized PCR Master mix | Promega | # M7122 |
| BODIPY™ 493/503 | ThermoFisher | # D3922 |
| BODIPY™ 581/591 C11 (Lipid Peroxidation Sensor) | ThermoFisher | #D3861 |
| Bovine Serum Albumin (BSA), Fraction V, Protease Free | Roche | #3117332001 |
| BSA-Palmitate (5 mM) | Cayman Chemical | #29558 |
| BSA-Oleic Acid | Sigma-Aldrich | #O3008 |
| Bovine Serum Albumin Standard Set | Bio-Rad Laboratories | #5000207 |
| Copper (II) sulfate pentahydrate | Sigma-Aldrich | #469130 |
| Concanavalin A from Canavalia ensiformis (Jack bean) | Sigma-Aldrich | #L6397-1MG |
| Cyano-myracrylamide (CMA) | MedChemExpress | #HY-155938 |
| 2-bromopalmitate (2BP) | MedChemExpress | #HY-111770 |
| 2-bromopalmitate (2BP) | Sigma-Aldrich | #21604 |
| eBioscience™ Cell Stimulation Cocktail (500X) | ThermoFisher | # 00-4970-03 |
| High-Capacity cDNA Reverse Transcription Kit | ThermoFisher | # 4374967 |
| Human Recombinant IL-2, | ThermoFisher | #SIL2 |
| Hydroxylamine solution, 10mL | Sigma-Aldrich | #467804-10ML |
| Normal Goat Serum Blocking Solution (S-1000-20) | Vector Laboratories | #S-1000-20 |
| Palmitic Acid Alkyne, 1mg | Cayman Chemical | #13266 |
| Protein A/G PLUS-Agarose | SantaCruz Biotechnology | # sc-2003 |
| TurboFect™ Transfection Reagent, | ThermoFisher | #R0531 |
| SYTOX™ Green Nucleic Acid Stain - 5 mM Solution in DMSO | ThermoFisher | # S7020 |
| Wheat Germ Agglutinin (WGA) Conjugates, 1mg | Biotium | #29026-1 |
| Nuclease-Free Water, 25ml | Promega | # P119C-C |
| anti-CD3/anti-CD28 beads | Life Technologies | #11132D |
| Lymphoprep | Cosmo Bio | # AXS-1115758 |
| RPMI 1640 Medium | ThermoFisher | #11875135 |
| TGX 4-15% SDS-PAGE | Bio-Rad Laboratories | #456-1083 |
| TGX 10% SDS-PAGE | Bio-Rad Laboratories | # 456-1036 |
| Nitrocellulose membranes | Bio-Rad Laboratories | #1620117 |
| TBS | Bio-Rad Laboratories | #170-6435 |
| Precision Plus Protein Dual Color Standards | Bio-Rad Laboratories | #161-0374 |
| Tris-Glycine-SDS Running Buffer (10X) | ||
| Tris-Glycine Transfer Buffer | ||
| Critical commercial assays | ||
| ATP Determination Kit, 200–1,000 assays | ThermoFisher | A22066 |
| Pierce™ BCA Protein Assay Kits | ThermoFisher | # 23227 |
| CyQUANT™ LDH Cytotoxicity Assay, fluorescence | ThermoFisher | # C20302 |
| DNeasy Blood and Tissue Kits for DNA Isolation | Qiagen | # 69506 |
| EasySep™ Human T Cell Isolation Kit | STEMCELL | #100-0695 |
| ELISA MAX™ Deluxe Set Human IL-1β | BioLegend | # 437004 |
| LDH-Cytox™ Assay Kit | BioLegend | #426401 |
| Lipid Droplet Isolation Kit | Cell Biolabs, Inc. | # MET-5011 |
| MojoSort™ Human CD4 T Cell Isolation Kit | BioLegend | #480130 |
| NE-PER™ Nuclear and Cytoplasmic Extraction | ThermoFisher | # 78835 |
| Pierce™ IP Lysis Buffer | ThermoFisher | #87787 |
| RIPA Lysis and Extraction Buffer | ThermoFisher | #89900 |
| Qubit™ dsDNA Quantification Assay Kits | ThermoFisher | # Q32851 |
| Ribonuclease A Solution, Molecular Biology Grade, 50 mg | ThermoFisher | J61996.MC |
| ZymoPure II Plasmid Maxiprep Kit | ZymoResearch | #412818 |
| ZymoPure Plasmid Mini Prep Kit | ZymoResearch | #404064 |
| Amaxa Human T Cell Nucleofector Kits | Lonza | # VPA-1002 |
| 4% paraformaldehyde | Santa Cruz Biotechnology | # sc-281692 |
| TMRM Deep Red | Invitrogen | # M7514 |
| Mem-PER™ Plus Membrane Protein Extraction Kit | ThermoFisher | #89842 |
| Fluoroshield™ with DAPI | Sigma-Aldrich | #F6057-20ML |
| Direct-zol RNA MiniPrep | Genesee Scientific | # 11-331 |
| Acetyl CoA Assay Kit | Abcam, USA | #AB87546 |
| Experimental models: Cell lines | ||
| Jurkat, Clone E6-1 | ATCC | #TIB-152 |
| 293T/17 SF [HEK 293T/17 SF] | ATCC | # ACS-4500 |
| Primary Human T cells | ||
| Experimental models: Organisms/strains | ||
| Human Synovium–NSG Mouse Chimeras (Immune Avatar) | Stanford University | N/A |
| Biological Samples | ||
| Human synovial tissue | Mayo Clinic | N/A |
| PBMC from healthy donors | Mayo Clinic | N/A |
| PBMC from patients with RA | Mayo Clinic | N/A |
| Plasma from healthy donors | Mayo Clinic | N/A |
| Plasma from patients with RA | Mayo Clinic | N/A |
| Oligonucleotides | ||
| qPCR primers | This Paper | See Table S2 |
| control siRNA | SantaCruz Biotechnology | sc-37007 |
| Human ADRP (PLIN2) siRNA | SantaCruz Biotechnology | sc-44841 |
| Human zDHHC5 siRNA | SantaCruz Biotechnology | sc-96568 |
| Human zDHHC20 siRNA | SantaCruz Biotechnology | sc-155498 |
| Deposited data | ||
| Data used to generate all figures | This paper | Data S1-Source |
| Recombinant DNA | ||
| PLIN2-Halo-tag | Gift from Dr. McNiven | |
| Software and algorithms | ||
| GraphPad Prism 10 | GraphPad software, inc. | RRID:SCR_002798 |
| ImageJ | National Institutes of Health | RRID:SCR_003070 |
| HD-Staining: Histology-based Digital Staining of Pathology Images | UT Southwestern Medical Center | https://lce.biohpc.swmed.edu/maskrcnn/ |
| ZEISS ZEN lite 3.1 | Carl Zeiss | RRID:SCR_018163 |
| FlowJo | BD | RRID:SCR_00852 |
Transmission electron microscopy
Cells were resuspended in McDowell’s and Trump’s fixative for 1 h at room temperature and then pelleted with a microcentrifuge. Cells were washed twice with 0.1 M phosphate buffer for 5 min. Liquid agar was added to the cell pellet and the cells were resuspended, followed immediately by centrifugation. Once the sample had cooled, the agar was removed, and the sample pellet removed with a razor blade and placed into 0.1 M phosphate buffer. After 2 rinses in 0.1 M phosphate buffer, pH 7.2, the sample was placed in 1% osmium tetroxide in the same buffer for 1 h at room temperature. The sample was rinsed twice in distilled water and dehydrated in an ethanolic series, culminating in two changes of 100% acetone. The cell pellet was then placed in a mixture of Spurr resin and acetone (1:1) for 30 min, followed by 2 h in 100% resin with 2 changes. The cell pellet was placed into 100% Spurr resin in an embedding mold and polymerized at 65 °C for ≥12 hr. Ultrathin (70–90 nm) sections were cut on an ultramicrotome with a diamond knife, stained with lead citrate, and examined with a JEOL 1400 transmission electron microscope.
Live cell imaging
Fresh solutions of Hoechst-33342 (2.5μM), (Invitrogen; #H21492) and SYTOX™ Green (1:30,000), (Invitrogen; #S7020) were prepared and added to CD4+ T cells for 30 min prior to the experiment. Images were acquired using the Keyence BZX800E system (Keyence). If needed, ImageJ software was applied to quantify Hoechst-33342 and SYTOX™ Green-positive cells.
Subcellular organelle analysis
Uropod length and numbers were manually quantified in polarized CD4+ T cells based on BODIPY™ 493/503 staining and cytoskeletal markers. Uropods were defined as rearward cell protrusions positioned opposite the leading-edge nucleus.
Lipid droplets (LD) per cell were counted from BODIPY 493/503-stained confocal images using ImageJ and manually annotated in TEM micrographs. LD size and area were measured using particle analysis tools in ImageJ.
For LD-plasma membrane (PM) spatial analysis, the distance from each LD to the inner face of the PM was measured in TEM images. LD located within 100 nm of the PM were classified as PM-contacting, and the number of such LD per cell was recorded.
Mean fluorescence intensities of PLIN2 and BODIPY were quantified on a per-cell basis using region-of-interest (ROI)–based analysis in ImageJ. Fluorescence thresholds were applied uniformly across all samples and experimental conditions.
For each experimental condition, 50–100 cells were analyzed across three biologically independent replicates. Data were compiled and statistically evaluated using GraphPad Prism 10.0.
Cell Size Analysis
Cells were stained with a plasma membrane specific dye (WGA; AF680) to clearly delineate cell boundaries prior to imaging. Fluorescence images were acquired under identical exposure settings across all conditions. Images were processed using ImageJ/Fiji (NIH, USA). The pixel-to-micrometer scale was calibrated using the microscope’s scale bar.
Stained cell perimeters were identified manually using the Freehand Selection Tool following grayscale conversion, thresholding, and binarization. Overlapping cells were separated using the Watershed function. Morphometric measurements including cell area (μm2), perimeter (μm), and Feret’s diameter were obtained using analyze followed by Measure. The equivalent circular diameter (μm) was calculated using the formula:
Here is the measured cell area. For each experimental group, at least [n = 30] cells were analyzed, and data were exported into Excel for further statistical analysis.
Histomorphometry of Synovial tissue
The training, validation, and testing set preparation was adapted from the method described by Wang et al., 2019 (Cancer Res 2020, 80(10): 2056–2066, https://doi.org/10.1158/0008-5472.CAN-19-1629 )68. 40x HD H&E-stained images were uploaded and used to quantify cell infiltration in the synovial tissue. (https://lce.biohpc.swmed.edu/maskrcnn/ ).
Cell membrane leakiness, SYTOX Green Uptake, and lytic cell death
Live-cell imaging was performed using the Keyence Cell Imaging System. Cells were stained with SYTOX™ Green to detect membrane-compromised (dead or dying) cells and Hoechst-33342 to label all nuclei. For each well, nine fields of view were captured under identical exposure settings. The ratio of SYTOX™ Green+ to DAPI+ cells was calculated to determine the percentage of dead or dying cells.
Lactate Dehydrogenase Quantification
For the analysis of extracellular lactate dehydrogenase (LDH) activity, both cell culture supernatants and tissue lysates were processed to remove intact cells and debris via centrifugation and filtration.
Cell Culture Supernatant: Conditioned media were collected from cultured cells and centrifuged at 1,000 × g for 5 min at 4°C to pellet residual cells. The clarified supernatant was directly used for LDH quantification. Tissue Lysates: Single-cell suspensions were obtained by enzymatic digestion of tissue using 1 mg/mL collagenase type IV (Worthington, LS004196) and 100 μg/mL DNase I (ZYMO Research, E1011-A) for 1 hour at 37°C. Tissue debris was removed sequentially using 70 μm and 40 μm sterile cell strainers. Total CD4+ T cells were isolated using human CD4+ T Cell Isolation Kits (BioLegend, #480130 or STEMCELL Technologies). Cell homogenates were centrifuged at 1,000 × g for 10 min at 4°C, and the resulting supernatants were filtered through a 0.2 μm syringe filter to eliminate particulate matter. LDH activity was measured using the CyQUANT™ LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Data are presented as fold change, calculated as the ratio of LDH activity between experimental and control conditions.
IL-1β Release Assay
Secreted IL-1β was measured in culture supernatants by enzyme-linked immunosorbent assay (ELISA). CD4+ T cells were activated with anti-CD3/anti-CD28 beads (1:3) for 72h. and culture supernatants were collected over the subsequent 24h. IL-1β was quantified using the Human IL-1β ELISA kit (#437004, BioLegend, San Diego) following the manufacturer’s instructions.
Extracellular DNA Quantification
Extracellular DNA was quantified from cell culture supernatants collected with and without lipid stress. Supernatants were cleared by centrifugation at 500 × g for 10 minutes to remove cellular debris, transferred to fresh tubes, and kept on ice. Total extracellular double-stranded DNA (dsDNA) was measured using the Qubit™ dsDNA HS Assay Kit (Thermo Fisher Scientific, Cat# Q32851) according to the manufacturer’s protocol. To distinguish nuclear and mitochondrial DNA, supernatants were first digested with proteinase K, followed by phenol–chloroform extraction and ethanol precipitation. Purified DNA was then subjected to PCR using primers targeting nuclear β2-microglobulin (B2M) and the mitochondrial D-loop region. PCR products were analyzed by agarose gel electrophoresis under native conditions.
Quantification of Extracellular LD
Cell-free supernatants were obtained by two-stage centrifugation at 500 × g for 10 minutes, followed by 3,000 × g for 10 minutes. The cleared supernatants were concentrated using Amicon Ultra-4 Centrifugal Filter Units (Millipore Sigma, 10 kDa cutoff) when necessary. Equal volumes of supernatant (10–15 μL) were denatured in Laemmli buffer, resolved by SDS-PAGE, and transferred to nitrocellulose membranes followed by staining with Ponceau S. Membranes were probed with anti-PLIN2 antibodies. Band intensities were quantified using ImageJ and normalized through the Ponceau S stain.
Cell-Free Nuclear DNA and Lipid Droplets in Mouse Plasma
Mouse plasma was collected via cardiac puncture into EDTA-coated tubes and centrifuged at 1,000 × g for 10 minutes at 4 °C to remove cellular components. The supernatant was carefully transferred to fresh tubes and stored at −80 °C until analysis.
Cell-free nuclear DNA (cf-nDNA) was quantified using the Qubit™ dsDNA HS Assay Kit (Thermo Fisher Scientific, Cat# Q32851) according to the manufacturer’s instructions. To confirm nuclear DNA specificity, DNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen), and quantitative PCR (qPCR) was performed using primers targeting the β2-microglobulin (B2M) gene. All qPCR reactions were run in technical triplicates.
Plasma lipid droplets (LD) were assessed by PLIN2 immunoblotting. Equal volumes of plasma were denatured in Laemmli sample buffer, resolved by SDS-PAGE, and transferred to nitrocellulose membranes. Membranes were stained with Ponceau S to confirm equal loading, then probed with an anti-PLIN2 antibody (Abcam, Cat# ab108323). Bands were visualized using chemiluminescence, and signal intensity was quantified using ImageJ.
Immunoblotting
Immunoblot analysis of whole cell lysates or subcellar extracts followed previously described protocols14. Cells were washed twice with cold phosphate-buffered saline (PBS) and lysed in RIPA buffer (Thermo Fisher Scientific, Cat# 89900) supplemented with Halt™ protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific). Lysates were incubated on ice for 30 minutes with periodic vertexing, then centrifuged at 14,000 × g for 15 minutes at 4 °C. Supernatants containing total cellular proteins were transferred to fresh tubes. Protein concentration was determined using the BCA Protein Assay Kit (BioRad) according to the manufacturer’s instructions. Equal amounts(20–50μg) of protein were mixed with 4× Laemmli sample buffer, boiled at 95 °C for 10 minutes, and resolved by SDS-PAGE using 4–15% or 10–12% polyacrylamide gels. Proteins were transferred to nitrocellulose membranes (Bio-Rad) using a semi-dry blotting system (Bio-Rad Trans-Blot Turbo). Membranes were blocked for 1 hour at room temperature in 5% BSA prepared in TBST (Tris-buffered saline with 0.1% Tween-20), followed by overnight incubation at 4 °C with primary antibodies diluted in blocking buffer. After three washes in TBST, membranes were incubated with HRP-conjugated secondary antibodies for 1 hour at room temperature. Signal detection was performed using ECL reagents (Bio-Rad), and chemiluminescence was captured with a ChemiDoc Imaging System (Bio-Rad).
For plasma immunoblotting, equal sample volumes (10–15μL) were loaded per lane. Ponceau S staining was performed prior to blocking to confirm uniform protein transfer. Densitometric quantification of bands was carried out using ImageJ software, with intensities normalized to total protein loading based on Ponceau S stain.
Immunoprecipitation
For pull-down assays, 500–1000 μg of total protein lysate was incubated with anti-PLIN2 antibody (1:100 dilution, CELL SIGNALING TECHNOLOGY) overnight at 4 °C on a rotator. The next day, Protein A/G magnetic beads (Thermo Fisher Scientific) were added and incubated for 2–3h at 4 °C with continuous rotation. Beads were washed three times with cold lysis buffer and once with PBS to remove non-specifically bound proteins. Immune complexes were eluted by boiling the beads in Laemmli sample buffer at 95 °C for 5–10 minutes. Eluates were resolved by SDS-PAGE and analyzed by immunoblotting as described above. A portion of the input lysate (5–10%) was loaded in parallel as a control. Membranes were probed with anti-zDHHC5 antibody to detect co-immunoprecipitated protein, and GAPDH was used as a loading control for input lysates.
Mass spectrometry analysis
Lipid droplets (LD) were isolated from activated CD4+ T cells using the Lipid Droplet Isolation Kit (Cell Biolabs, Cat# MET-5011). Isolated LD were washed in PBS and subjected to organic extraction using chloroform/acetone (1:1, v/v) to remove lipids. Protein pellets were air-dried and resuspended in 8 M urea in 50 mM ammonium bicarbonate for digestion. Protein concentration was measured using the BCA Protein Assay Kit (Bio-Rad). 50–100 μg of protein per sample was reduced with 10 mM dithiothreitol (DTT), alkylated with 20 mM iodoacetamide, and digested overnight with trypsin (Promega, 1:50 enzyme-to-substrate ratio) at 37 °C. Peptides were desalted using C18 spin columns (Thermo Scientific) and dried under vacuum.
Samples were analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS) on a Thermo Scientific Q Exactive Orbitrap mass spectrometer coupled to an EASY-nLC 1200 system. Peptides were separated on a 75 μm × 25 cm C18 column using a 120-minute gradient of 5–35% acetonitrile with 0.1% formic acid. MS1 scans were acquired at a resolution of 70,000, followed by data-dependent MS2 scans at 17,500 resolutions for the top 15 precursors.
Raw data files were analyzed using MaxQuant (v2.6.7.0) with the Andromeda search engine, against the UniProt human reference proteome. Carbamidomethylation of cysteines was set as a fixed modification; oxidation (M) and N-terminal acetylation were considered variable. A 1% false discovery rate (FDR) was applied at the peptide and protein levels. Label-free quantification (LFQ) was enabled.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were conducted independently at least three times, and the resulting data were combined for analysis. No animals or samples that underwent successful procedures or treatments were excluded. Statistical analyses were performed using GraphPad Prism (GraphPad Software). For comparisons between two groups, the Mann–Whitney U test or paired Wilcoxon test was applied when the group size exceeded five. For smaller sample sizes (≤5), and when data met the assumptions of normality and variance, a parametric t-test was used. To correct for multiple comparisons, Hochberg’s step-down procedure was applied to control the family-wise error rate at 0.05. For analyses involving three or more groups, one-way ANOVA followed by Tukey’s post hoc test and multiple t test were performed. All data points were included in the analysis, and Grubbs’ test did not detect any outliers. Results are expressed as mean ± SEM.
For proteomics data, pathway enrichment analyses—such as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)—were carried out using Enrichr (https://maayanlab.cloud/Enrichr) and Ingenuity Pathway Analysis (IPA, QIAGEN), applying a significance threshold of P < 0.05.
In rheumatoid arthritis (RA), the tissue metabolic environment reprograms CD4+T cells.
Lipid droplets in RA CD4+T cells sequester Gasdermin D and its activator zDHHC5.
RA lipid droplets act as killer organelles that induce pyroptotic membrane lysis.
Dying T cells expel intracellular contents that drive autoimmune tissue inflammation.
Kumar et al. identify a metabolically controlled trait of CD4+ T cells in autoimmune disease. Exposed to fatty acids in rheumatoid joints, they form lipid droplets containing pore-forming Gasdermin D and its activator zDHHC5. These droplets induce plasma membrane lysis, resulting in the leakage of intracellular contents and tissue inflammation.
Supplementary Material
SUPPLEMENTAL INFORMATION
Document S1. Figures S1–S10, and Table S2
Document S2. Table S1_Differential expression analysis for proteomics
Document S3. Table S3_List of primers
Data S1. Unprocessed blots and source data for graphs, related to Figures 1–8 and S1–S10
ACKNOWLEDGMENTS
This work was supported by the United States National Institutes of Health, R01AG045779, R01AI108891, R01AI108906, R01HL117913, R01HL142068, U01AI179609, R01AR042527, R01AI184360, R01AI129191, the Encrantz Family and Southwell Family Discoveryfunds, and the Mark and Mary Davis Initiative in Rheumatoid Arthritis.
Footnotes
DECLARATION OF INTERESTS
C.M.W. has received consulting fees from AbbVie, Bristol Myers Squibb, Novartis, Ono Pharmaceutical, Boehringer-Ingelheim, and Sparrow Pharmaceuticals. J.J.G. has received consulting fees and stock options from Retro Biosciences.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
REFERENCES
- 1.Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, Mason J, Sattar N, McMurray JJV, McInnes IB, et al. (2023). Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878–1890. 10.1016/S0140-6736(23)00457-9. [DOI] [PubMed] [Google Scholar]
- 2.Lee YS, and Olefsky J (2021). Chronic tissue inflammation and metabolic disease. Genes Dev 35, 307–328. 10.1101/gad.346312.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Li Y, Shen Y, Jin K, Wen Z, Cao W, Wu B, Wen R, Tian L, Berry GJ, Goronzy JJ, and Weyand CM (2019). The DNA Repair Nuclease MRE11A Functions as a Mitochondrial Protector and Prevents T Cell Pyroptosis and Tissue Inflammation. Cell Metab 30, 477–492 e476. 10.1016/j.cmet.2019.06.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Weyand CM, and Goronzy JJ (2021). The immunology of rheumatoid arthritis. Nat Immunol 22, 10–18. 10.1038/s41590-020-00816-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Qiu J, Wu B, Goodman SB, Berry GJ, Goronzy JJ, and Weyand CM (2021). Metabolic Control of Autoimmunity and Tissue Inflammation in Rheumatoid Arthritis. Front Immunol 12, 652771. 10.3389/fimmu.2021.652771. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Weyand CM, and Goronzy JJ (2025). Immune Aging in Rheumatoid Arthritis. Arthritis Rheumatol 77, 792–804. 10.1002/art.43105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Chemin K, Gerstner C, and Malmstrom V (2019). Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis. Front Immunol 10, 353. 10.3389/fimmu.2019.00353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Macallan DC, Wallace D, Zhang Y, De Lara C, Worth AT, Ghattas H, Griffin GE, Beverley PC, and Tough DF (2004). Rapid turnover of effector-memory CD4(+) T cells in healthy humans. J Exp Med 200, 255–260. 10.1084/jem.20040341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hu Z, Zhao TV, Huang T, Ohtsuki S, Jin K, Goronzy IN, Wu B, Abdel MP, Bettencourt JW, Berry GJ, et al. (2022). The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages. Nat Metab 4, 759–774. 10.1038/s42255-022-00585-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Weyand CM, Wu B, and Goronzy JJ (2020). The metabolic signature of T cells in rheumatoid arthritis. Curr Opin Rheumatol 32, 159–167. 10.1097/BOR.0000000000000683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Li Y, Goronzy JJ, and Weyand CM (2018). DNA damage, metabolism and aging in pro-inflammatory T cells: Rheumatoid arthritis as a model system. Exp Gerontol 105, 118–127. 10.1016/j.exger.2017.10.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Shen Y, Wen Z, Li Y, Matteson EL, Hong J, Goronzy JJ, and Weyand CM (2017). Metabolic control of the scaffold protein TKS5 in tissue-invasive, proinflammatory T cells. Nat Immunol 18, 1025–1034. 10.1038/ni.3808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Weyand CM, and Goronzy JJ (2025). Metabolic checkpoints in rheumatoid arthritis. Semin Arthritis Rheum 70S, 152586. 10.1016/j.semarthrit.2024.152586. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wu B, Zhao TV, Jin K, Hu Z, Abdel MP, Warrington KJ, Goronzy JJ, and Weyand CM (2021). Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. Nat Immunol 22, 1551–1562. 10.1038/s41590-021-01065-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Wu B, Qiu J, Zhao TV, Wang Y, Maeda T, Goronzy IN, Akiyama M, Ohtsuki S, Jin K, Tian L, et al. (2020). Succinyl-CoA Ligase Deficiency in Pro-inflammatory and Tissue-Invasive T Cells. Cell Metab 32, 967–980 e965. 10.1016/j.cmet.2020.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Hunt EG, Hurst KE, Riesenberg BP, Kennedy AS, Gandy EJ, Andrews AM, Del Mar Alicea Pauneto C., Ball LE., Wallace ED, Gao P, et al. (2024). Acetyl-CoA carboxylase obstructs CD8(+) T cell lipid utilization in the tumor microenvironment. Cell Metab 36, 969–983 e910. 10.1016/j.cmet.2024.02.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Olzmann JA, and Carvalho P (2019). Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol 20, 137–155. 10.1038/s41580-018-0085-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Jarc E, and Petan T (2019). Lipid Droplets and the Management of Cellular Stress. Yale J Biol Med 92, 435–452. [PMC free article] [PubMed] [Google Scholar]
- 19.Mathiowetz AJ, and Olzmann JA (2024). Lipid droplets and cellular lipid flux. Nat Cell Biol 26, 331–345. 10.1038/s41556-024-01364-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Roberts MA, Deol KK, Mathiowetz AJ, Lange M, Leto DE, Stevenson J, Hashemi SH, Morgens DW, Easter E, Heydari K, et al. (2023). Parallel CRISPR-Cas9 screens identify mechanisms of PLIN2 and lipid droplet regulation. Dev Cell 58, 1782–1800 e1710. 10.1016/j.devcel.2023.07.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Bezawork-Geleta A, Devereux CJ, Keenan SN, Lou J, Cho E, Nie S, De Souza DP, Narayana VK, Siddall NA, Rodrigues CHM, et al. (2025). Proximity proteomics reveals a mechanism of fatty acid transfer at lipid droplet-mitochondria- endoplasmic reticulum contact sites. Nat Commun 16, 2135. 10.1038/s41467-025-57405-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Krahmer N, and Mann M (2019). Catching Lipid Droplet Contacts by Proteomics. Contact (Thousand Oaks) 2, 2515256419859186. 10.1177/2515256419859186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Liang JJ, Fraser IDC, and Bryant CE (2021). Lipid regulation of NLRP3 inflammasome activity through organelle stress. Trends Immunol 42, 807–823. 10.1016/j.it.2021.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Bosch M, Sanchez-Alvarez M, Fajardo A, Kapetanovic R, Steiner B, Dutra F, Moreira L, Lopez JA, Campo R, Mari M, et al. (2020). Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense. Science 370. 10.1126/science.aay8085. [DOI] [Google Scholar]
- 25.Bosch M, Parton RG, and Pol A (2020). Lipid droplets, bioenergetic fluxes, and metabolic flexibility. Semin Cell Dev Biol 108, 33–46. 10.1016/j.semcdb.2020.02.010. [DOI] [PubMed] [Google Scholar]
- 26.Bosch M, Sweet MJ, Parton RG, and Pol A (2021). Lipid droplets and the host-pathogen dynamic: FATal attraction? J Cell Biol 220. 10.1083/jcb.202104005. [DOI] [Google Scholar]
- 27.Chang MH, Levescot A, Nelson-Maney N, Blaustein RB, Winden KD, Morris A, Wactor A, Balu S, Grieshaber-Bouyer R, Wei K, et al. (2021). Arthritis flares mediated by tissue-resident memory T cells in the joint. Cell Rep 37, 109902. 10.1016/j.celrep.2021.109902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zhang F, Jonsson AH, Nathan A, Millard N, Curtis M, Xiao Q, Gutierrez-Arcelus M, Apruzzese W, Watts GFM, Weisenfeld D, et al. (2023). Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616–624. 10.1038/s41586-023-06708-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Mustonen A-M, Tollis S, Käkelä R, Sihvo SP, Palosaari S, Pohjanen V-M, Yli-Hallila A, Lehenkari P, and Nieminen P (2023). Increased n-6 Polyunsaturated Fatty Acids Indicate Pro- and Anti-Inflammatory Lipid Modifications in Synovial Membranes with Rheumatoid Arthritis. Inflammation 46, 1396–1413. 10.1007/s10753-023-01816-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mustonen A-M, Käkelä R, Lehenkari P, Huhtakangas J, Turunen S, Joukainen A, Kääriäinen T, Paakkonen T, Kröger H, and Nieminen P (2019). Distinct fatty acid signatures in infrapatellar fat pad and synovial fluid of patients with osteoarthritis versus rheumatoid arthritis. Arthritis Research & Therapy 21, 124. 10.1186/s13075-019-1914-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kaushik S, and Cuervo AM (2015). Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat Cell Biol 17, 759–770. 10.1038/ncb3166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Chiariello A, Rossetti L, Valente S, Pasquinelli G, Sollazzo M, Iommarini L, Porcelli AM, Tognocchi M, Conte G, Santoro A, et al. (2024). Downregulation of PLIN2 in human dermal fibroblasts impairs mitochondrial function in an age-dependent fashion and induces cell senescence via GDF15. Aging Cell 23, e14111. 10.1111/acel.14111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Zhu C, Xu S, Jiang R, Yu Y, Bian J, and Zou Z (2024). The gasdermin family: emerging therapeutic targets in diseases. Signal Transduction and Targeted Therapy 9, 87. 10.1038/s41392-024-01801-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lieberman J, Wu H, and Kagan JC (2019). Gasdermin D activity in inflammation and host defense. Sci Immunol 4. 10.1126/sciimmunol.aav1447. [DOI] [Google Scholar]
- 35.Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, et al. (2023). CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618, 1033–1040. 10.1038/s41586-023-06199-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sundaram B, Tweedell RE, Prasanth Kumar S, and Kanneganti TD (2024). The NLR family of innate immune and cell death sensors. Immunity 57, 674–699. 10.1016/j.immuni.2024.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Zhang N, Zhang J, Yang Y, Shan H, Hou S, Fang H, Ma M, Chen Z, Tan L, and Xu D (2024). A palmitoylation–depalmitoylation relay spatiotemporally controls GSDMD activation in pyroptosis. Nature Cell Biology 26, 757–769. 10.1038/s41556-024-01397-9. [DOI] [PubMed] [Google Scholar]
- 38.Balasubramanian A, Hsu AY, Ghimire L, Tahir M, Devant P, Fontana P, Du G, Liu X, Fabin D, Kambara H, et al. (2024). The palmitoylation of gasdermin D directs its membrane translocation and pore formation during pyroptosis. Sci Immunol 9, eadn1452. 10.1126/sciimmunol.adn1452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Ohno Y, Kihara A, Sano T, and Igarashi Y (2006). Intracellular localization and tissue-specific distribution of human and yeast DHHC cysteine-rich domain-containing proteins. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1761, 474–483. 10.1016/j.bbalip.2006.03.010. [DOI] [PubMed] [Google Scholar]
- 40.Liu H, Wen S, Xu C, Kang X, and Kong E (2025). Mechanisms and functional implications of ZDHHC5 in cellular physiology and disease. Journal of Lipid Research 66. 10.1016/j.jlr.2025.100793. [DOI] [Google Scholar]
- 41.Lan T, Delalande C, and Dickinson BC (2021). Inhibitors of DHHC family proteins. Curr Opin Chem Biol 65, 118–125. 10.1016/j.cbpa.2021.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Liu D, Cruz-Cosme R, Wu Y, Leibowitz J, and Tang Q (2024). 2-Bromopalmitate depletes lipid droplets to inhibit viral replication. J Virol 98, e0017124. 10.1128/jvi.00171-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Zadoorian A, Du X, and Yang H (2023). Lipid droplet biogenesis and functions in health and disease. Nat Rev Endocrinol 19, 443–459. 10.1038/s41574-023-00845-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Cohen S (2018). Lipid Droplets as Organelles. Int Rev Cell Mol Biol 337, 83–110. 10.1016/bs.ircmb.2017.12.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Zhang S, Lv K, Liu Z, Zhao R, and Li F (2024). Fatty acid metabolism of immune cells: a new target of tumour immunotherapy. Cell Death Discov 10, 39. 10.1038/s41420-024-01807-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Yang Z, Shen Y, Oishi H, Matteson EL, Tian L, Goronzy JJ, and Weyand CM (2016). Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. Sci Transl Med 8, 331ra338. 10.1126/scitranslmed.aad7151. [DOI] [Google Scholar]
- 47.Yang Z, Fujii H, Mohan SV, Goronzy JJ, and Weyand CM (2013). Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J Exp Med 210, 2119–2134. 10.1084/jem.20130252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Garcia-Jimenez C, and Goding CR (2019). Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming. Cell Metab 29, 254–267. 10.1016/j.cmet.2018.11.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Jin J, Zhang H, Weyand CM, and Goronzy JJ (2021). Lysosomes in T Cell Immunity and Aging. Front Aging 2, 809539. 10.3389/fragi.2021.809539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Wen Z, Jin K, Shen Y, Yang Z, Li Y, Wu B, Tian L, Shoor S, Roche NE, Goronzy JJ, and Weyand CM (2019). N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. Nat Immunol 20, 313–325. 10.1038/s41590-018-0296-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Zhang W, Xu L, Zhu L, Liu Y, Yang S, and Zhao M (2021). Lipid Droplets, the Central Hub Integrating Cell Metabolism and the Immune System. Front Physiol 12, 746749. 10.3389/fphys.2021.746749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Lim SA, Su W, Chapman NM, and Chi H (2022). Lipid metabolism in T cell signaling and function. Nat Chem Biol 18, 470–481. 10.1038/s41589-022-01017-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Hunt EG, Andrews AM, Larsen SR, and Thaxton JE (2022). The ER-Mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors. Front Cell Dev Biol 10, 867341. 10.3389/fcell.2022.867341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, Sudderth J, Calvaruso MA, Lumata L, Mitsche M, et al. (2014). Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell 56, 414–424. 10.1016/j.molcel.2014.09.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Johri N, Varshney S, Gandha S, Maurya A, Mittal P, Jangra S, Garg R, and Saraf A (2023). Association of cardiovascular risks in rheumatoid arthritis patients: Management, treatment and future perspectives. Health Sciences Review 8, 100108. 10.1016/j.hsr.2023.100108. [DOI] [Google Scholar]
- 56.Kremer JM (2000). n-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr 71, 349S–351S. 10.1093/ajcn/71.1.349s. [DOI] [PubMed] [Google Scholar]
- 57.Sun L, Zhu J, Mi S, Li Y, Wang T, and Li Y (2021). Causal association of monounsaturated fatty acids with rheumatoid arthritis but not osteoarthritis: A two-sample Mendelian randomization study. Nutrition 91-92, 111363. 10.1016/j.nut.2021.111363. [DOI] [Google Scholar]
- 58.Pettinella C, Lee SH, Cipollone F, and Blair IA (2007). Targeted quantitative analysis of fatty acids in atherosclerotic plaques by high sensitivity liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 850, 168–176. 10.1016/j.jchromb.2006.11.023. [DOI] [Google Scholar]
- 59.Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, and Grimble RF (2003). Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477–485. 10.1016/s0140-6736(03)12468-3. [DOI] [PubMed] [Google Scholar]
- 60.Malgapo MIP, and Linder ME (2021). Substrate recruitment by zDHHC protein acyltransferases. Open Biol 11, 210026. 10.1098/rsob.210026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Tan Y, and Buch MH (2022). ‘Difficult to treat’ rheumatoid arthritis: current position and considerations for next steps. RMD Open 8. 10.1136/rmdopen-2022-002387. [DOI] [Google Scholar]
- 62.Buch MH, Eyre S, and McGonagle D (2021). Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 17, 17–33. 10.1038/s41584-020-00541-7. [DOI] [PubMed] [Google Scholar]
- 63.Krenn V, Morawietz L, Burmester GR, Kinne RW, Mueller-Ladner U, Muller B, and Haupl T (2006). Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, 358–364. 10.1111/j.1365-2559.2006.02508.x. [DOI] [PubMed] [Google Scholar]
- 64.Najm A, le Goff B, Venet G, Garraud T, Amiaud J, Biha N, Charrier C, Touchais S, Crenn V, Blanchard F, and Krenn V (2019). IMSYC immunologic synovitis score: A new score for synovial membrane characterization in inflammatory and non-inflammatory arthritis. Joint Bone Spine 86, 77–81. 10.1016/j.jbspin.2018.04.004. [DOI] [PubMed] [Google Scholar]
- 65.Li Y, Shen Y, Hohensinner P, Ju J, Wen Z, Goodman SB, Zhang H, Goronzy JJ, and Weyand CM (2016). Deficient Activity of the Nuclease MRE11A Induces T Cell Aging and Promotes Arthritogenic Effector Functions in Patients with Rheumatoid Arthritis. Immunity 45, 903–916. 10.1016/j.immuni.2016.09.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Zhao TV, Hu Z, Ohtsuki S, Jin K, Wu B, Berry GJ, Frye RL, Goronzy JJ, and Weyand CM (2022). Hyperactivity of the CD155 immune checkpoint suppresses anti-viral immunity in patients with coronary artery disease. Nat Cardiovasc Res 1, 634–648. 10.1038/s44161-022-00096-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Ye Z, Shen Y, Jin K, Qiu J, Hu B, Jadhav RR, Sheth K, Weyand CM, and Goronzy JJ (2021). Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation. Nat Commun 12, 907. 10.1038/s41467-021-21242-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Wang S, Rong R, Yang DM, Fujimoto J, Yan S, Cai L, Yang L, Luo D, Behrens C, Parra ER, et al. (2020). Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer. Cancer Res 80, 2056–2066. 10.1158/0008-5472.CAN-19-1629. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Source data and original blots are included in Data S1. This manuscript did not generate new code.
